<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004844.pub3" GROUP_ID="SYMPT" ID="919303072811525092" MERGED_FROM="" MODIFIED="2015-11-27 12:20:35 +0000" MODIFIED_BY="Anna Hobson" REVIEW_NO="91" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2015-11-27 12:18:34 +0000" MODIFIED_BY="Anna Hobson">
<TITLE MODIFIED="2013-06-03 14:06:11 +0100" MODIFIED_BY="Stefan Seidel">Antipsychotics for acute and chronic pain in adults</TITLE>
<CONTACT>
<PERSON ID="90C3128382E26AA2015C072995F716C8" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Stefan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Seidel</LAST_NAME>
<SUFFIX/>
<POSITION>Doctor</POSITION>
<EMAIL_1>stefan.seidel@meduniwien.ac.at</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Medical University of Vienna</ORGANISATION>
<ADDRESS_1>Währinger Straße 13a</ADDRESS_1>
<ADDRESS_2/>
<CITY>Vienna</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-11-27 12:18:02 +0000" MODIFIED_BY="Anna Hobson">
<PERSON ID="90C3128382E26AA2015C072995F716C8" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Stefan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Seidel</LAST_NAME>
<SUFFIX/>
<POSITION>Doctor</POSITION>
<EMAIL_1>stefan.seidel@meduniwien.ac.at</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Medical University of Vienna</ORGANISATION>
<ADDRESS_1>Währinger Straße 13a</ADDRESS_1>
<ADDRESS_2/>
<CITY>Vienna</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17330" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Martin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Aigner</LAST_NAME>
<SUFFIX/>
<POSITION>Behavioural Medicine Pain Clinic</POSITION>
<EMAIL_1>Martin.Aigner@tulln.lknoe.at</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry</DEPARTMENT>
<ORGANISATION>Medical University of Vienna</ORGANISATION>
<ADDRESS_1>Währinger Gürtel 18-20</ADDRESS_1>
<ADDRESS_2/>
<CITY>Vienna</CITY>
<ZIP>AT-1090</ZIP>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1>+43 1 40400 3603</PHONE_1>
<PHONE_2/>
<FAX_1>+43 1 40400 3388</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18376" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ossege</LAST_NAME>
<SUFFIX/>
<POSITION>Klinische Abteilung für Sozialpsychiatrie und Evaluationsforschung</POSITION>
<EMAIL_1>michael.ossege@meduniwien.ac.at</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry</DEPARTMENT>
<ORGANISATION>Medical University of Vienna</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Vienna</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="90C310CE82E26AA2015C0729B655B05F" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Elisabeth</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pernicka</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>elisabeth.pernicka@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical Statistics</DEPARTMENT>
<ORGANISATION>Medical University of Vienna</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Vienna</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12666" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Brigitte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wildner</LAST_NAME>
<SUFFIX>MSc</SUFFIX>
<POSITION/>
<EMAIL_1>brigitte.wildner@meduniwien.ac.at</EMAIL_1>
<EMAIL_2>brigitte.wildner@univie.ac.at</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Information Retrieval Office</DEPARTMENT>
<ORGANISATION>University Library of the Medical University of Vienna</ORGANISATION>
<ADDRESS_1>Währinger Gürtel 18-20</ADDRESS_1>
<ADDRESS_2/>
<CITY>Vienna</CITY>
<ZIP>1090</ZIP>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1>+43-1-4040160 ext: 26125</PHONE_1>
<PHONE_2/>
<FAX_1>+43-1-40160 926 001</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8888" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Thomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sycha</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant</POSITION>
<EMAIL_1>thomas.sycha@meduniwien.ac.at</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Medical University of Vienna</ORGANISATION>
<ADDRESS_1>Währinger Gürtel 18-20</ADDRESS_1>
<ADDRESS_2/>
<CITY>Vienna</CITY>
<ZIP>A-1090</ZIP>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1>+43 1 40400 3120</PHONE_1>
<PHONE_2/>
<FAX_1>+43 1 40400 6215</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-09-04 11:36:17 +0100" MODIFIED_BY="Joanne Abbott">
<UP_TO_DATE>
<DATE DAY="21" MONTH="8" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="1" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="1" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2015-11-27 12:18:34 +0000" MODIFIED_BY="Anna Hobson">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2015-11-27 12:18:34 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="27" MONTH="11" YEAR="2015"/>
<DESCRIPTION>
<P>See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-11-27 12:18:17 +0000" MODIFIED_BY="Anna Hobson">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-11-27 12:18:17 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="7" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>Inclusion of studies on prochlorperazine and droperidol. See <LINK REF="FBK-01" TYPE="FEEDBACK">Feedback 1</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-03-24 15:39:41 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Slight amendment to wording of search strategy.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-09-04 14:29:03 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="21" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>This search found five new studies which were all excluded, so the review remains the same as previously.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-09-04 14:29:06 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="7" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>This review is an update of the original review published in <I>The Cochrane Library</I> in 2008. See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-12-10 16:00:22 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="9" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Psychiatry, University of Vienna Medical School</NAME>
<COUNTRY CODE="AT">Austria</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-11-27 12:20:35 +0000" MODIFIED_BY="Anna Hobson">
<SUMMARY MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Anna Hobson">
<TITLE>Analgesic effects of antipsychotics in acute and chronic painful states</TITLE>
<SUMMARY_BODY MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Anna Hobson">
<P>Medicines called &#8216;antipsychotics&#8217;, which are used to treat some mental health conditions, are sometimes used to treat chronic pain. A new type of these medicines called 'atypical antipsychotics' is available, with fewer side effects and some additional benefits. The review authors assessed the effect of these medicines on pain and their side effects. Based on 5 out of 11 included trials there were some beneficial effects of antipsychotics in the treatment of acute and chronic pain. Analysis of these studies showed a significant reduction in pain after administration of the antipsychotic compared to placebo or another medicine, however these results were based on small studies and therefore they may be unreliable. It is also important to consider the unwanted effects that these medicines might cause.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-09-04 14:22:58 +0100" MODIFIED_BY="Jessica Thomas">
<ABS_BACKGROUND MODIFIED="2013-08-21 14:21:11 +0100" MODIFIED_BY="Jessica Thomas">
<P>This is an updated version of the original Cochrane review published in Issue 4, 2008. The role of antipsychotics as adjuvant analgesics is a subject of longstanding controversy. Neuroleptanalgesia (that is a state of quiescence, altered awareness, and analgesia produced by a combination of taking an opioid analgesic and an antipsychotic), an established term for the management of acute pain, was shown to negatively influence disease course and total mortality in unstable angina patients. Nevertheless, antipsychotics are used to treat chronic pain (for example chronic headache, fibromyalgia and diabetic neuropathia). With atypical antipsychotics, a new class of antipsychotics, both fewer extrapyramidal side effects and additional benefits may be available.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-08-21 14:21:14 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the analgesic efficacy and adverse effects of antipsychotics in acute or chronic pain in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-09-04 14:22:58 +0100" MODIFIED_BY="[Empty name]">
<P>The following databases were searched: CENTRAL, on <I>The Cochrane Library</I>, (Issue 12 of 12, 2012); MEDLINE (1966 to 11/1/2013); EMBASE (1980 to 2013 week 03) and PsycINFO 1806 to Jan week 3 2013. Searches were run originally in 2007 and then again in 2011 and 2013.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) of adults prescribed any dose of an oral antipsychotic for acute or chronic pain, where subjective pain assessment was described as either the primary or a secondary outcome, were included in this review.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-08-21 14:21:29 +0100" MODIFIED_BY="Anna Hobson">
<P>Data were extracted by two independent review authors, and results were compared for differences. Discrepancies were resolved by discussion. All trials were quality scored according to the methods set out in section six of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-08-21 14:22:09 +0100" MODIFIED_BY="Anna Hobson">
<P>A total of 770 participants were involved in the 11 included studies. Data from five included randomised double-blind studies showed beneficial effects of antipsychotics in the treatment of acute and chronic pain. Quantitative analysis of these studies showed a significant reduction of mean pain intensity after administration of the antipsychotic compared to placebo or another active compound, weighted mean difference (WMD) -1.78 (95% CI -2.71 to -0.85) for the continuous data; and relative risk (RR) 0.43 (95% CI 0.25 to 0.73), number needed to treat to benefit (NNT) 2.6 for the dichotomous data. Nevertheless, the test for heterogeneity was significant for both the continuous data (P = 0.0007) and the dichotomous data (P = 0.04). Obviously this makes the calculated NNT less reliable and caution is warranted when interpreting these results.</P>
<P>The most frequently reported adverse effects were extrapyramidal (that is involuntary movements, parkinsonism and akathisia) and sedating effects.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="[Empty name]">
<P>The recent search found five new studies which were all excluded, so the review remains the same as previously.</P>
<P>Antipsychotics might be used as an add-on therapy in the treatment of painful conditions. Nevertheless, extrapyramidal and sedating side effects have to be considered before using antipsychotics for treating painful conditions.</P>
<P>Results for antipsychotics in the treatment of different painful conditions are mixed and most sample sizes in the reviewed RCTs are small. Further studies on atypical antipsychotics in larger double-blind placebo-controlled studies that include standardised pain assessment and documentation are warranted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-11-18 09:46:09 +0000" MODIFIED_BY="Jessica Thomas">
<BACKGROUND MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Jessica Thomas">
<P>This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (2008, Issue 4).</P>
<P>Antipsychotics (also called neuroleptics) can be classified according to their chemical structure into tricyclic antipsychotics (phenothiazines, thioxanthenes), butyrophenones, substituted benzamides and other chemical substances (dichlorphenyl-piperazinyl-chiloninones, diphenylbutylpiperidines, benzisoxazoles, benzisothiazylpiperazines, phenylpiperidines). Atypical antipsychotics differ from classical antipsychotics, or 'first generation antipsychotics', in the extrapyramidal side effects, effectiveness in negative symptomatology, and lower prolactin elevations with comparable antipsychotic efficacy. Classical antipsychotics have a predominant dopamine D2 antagonism, whereas the atypical antipsychotics also address other neurotransmitter systems, for example the serotonin system. In clinical practice cardiovascular side effects, especially a prolonged QTc, have to be kept in mind when treating patients with antipsychotics.</P>
<P>The therapeutic effects of antipsychotics make them a potential choice as drugs in the treatment of pain. To date the role of classic antipsychotics such as adjuvant analgesics has been a subject of longstanding controversy. Their clinical usefulness in the management of pain is questioned (<LINK REF="REF-Patt-1994" TYPE="REFERENCE">Patt 1994</LINK>). Neuroleptanalgesia (that is a state of quiescence, altered awareness, and analgesia produced by a combination of taking an opioid analgesic and an antipsychotic) as an established term for the management of acute pain was shown to negatively influence disease course and total mortality in unstable angina patients (<LINK REF="REF-Burduk-2000" TYPE="REFERENCE">Burduk 2000</LINK>).</P>
<P>Antipsychotics are also used in a variety of different chronic pain states, from cancer pain (<LINK REF="REF-Bloomfield-1964" TYPE="REFERENCE">Bloomfield 1964</LINK>; <LINK REF="REF-Breitbart-1998" TYPE="REFERENCE">Breitbart 1998</LINK>; <LINK REF="REF-Khojainova-2002" TYPE="REFERENCE">Khojainova 2002</LINK>) to chronic non-cancer pain (<LINK REF="REF-Merskey-1997" TYPE="REFERENCE">Merskey 1997</LINK>) as in chronic headache or chronic refractory headache (<LINK REF="STD-Hakkarainen-1977" TYPE="STUDY">Hakkarainen 1977</LINK>; <LINK REF="REF-Lu-2000" TYPE="REFERENCE">Lu 2000</LINK>; <LINK REF="REF-Silberstein-2002" TYPE="REFERENCE">Silberstein 2002</LINK>), fibromyalgia (<LINK REF="REF-Kiser-2001" TYPE="REFERENCE">Kiser 2001</LINK>), musculoskeletal pain (<LINK REF="REF-Bloomfield-1964" TYPE="REFERENCE">Bloomfield 1964</LINK>), low back pain (<LINK REF="REF-Bloomfield-1964" TYPE="REFERENCE">Bloomfield 1964</LINK>; <LINK REF="REF-Jermyn-2001" TYPE="REFERENCE">Jermyn 2001</LINK>), chronic pain in older patients (<LINK REF="REF-Feinberg-2000" TYPE="REFERENCE">Feinberg 2000</LINK>), pain in AIDS (<LINK REF="REF-Breitbart-1998" TYPE="REFERENCE">Breitbart 1998</LINK>), post-herpes zoster (<LINK REF="REF-Gobel-1997" TYPE="REFERENCE">Gobel 1997</LINK>; <LINK REF="REF-Montilla-1963" TYPE="REFERENCE">Montilla 1963</LINK>), chronic facial pain (<LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>; <LINK REF="REF-Peschen_x002d_Rosin-2002" TYPE="REFERENCE">Peschen-Rosin 2002</LINK>), and diabetic neuropathia (<LINK REF="STD-Gomez_x002d_Perez-1985" TYPE="STUDY">Gomez-Perez 1985</LINK>).</P>
<P>In a meta-analysis on the analgesic potency of antipsychotics by Nix and colleagues (<LINK REF="REF-Nix-1998" TYPE="REFERENCE">Nix 1998</LINK>) only 10 out of 15 studies with a higher statistical power described a possible analgesic effect. None of the studies identified could differentiate between the effects of analgesia and sedation of the drugs used.</P>
<P>The way antipsychotics work to relieve pain is still under debate and may differ between different agents. For some pain syndromes (for example migraine) antidopaminergic properties may mediate the analgesic effects. Also, the serotonin antagonism of some antipsychotic agents is believed to mediate the analgesic effects (<LINK REF="REF-Schreiber-1999" TYPE="REFERENCE">Schreiber 1999</LINK>). Additionally, for some antipsychotics (for example olanzapine) their agonistic activity at alpha2-adrenoceptors is believed to mediate analgesic effects (<LINK REF="REF-Silberstein-2002" TYPE="REFERENCE">Silberstein 2002</LINK>).</P>
<P>Besides discussions about the potential of antipsychotics to be used as analgesics, a potent antinociceptive effect has been shown for risperidone, an atypical antipsychotic, in an in vivo animal pain model (that is the tail-flick assay). Further evaluation of risperidone with selective opioid antagonists revealed the involvement of µ1-, µ2-, and kappa1-opioids and, to a lesser extent, delta-opioid mechanisms. For olanzapine the alpha2-adrenoceptors and to a lesser extent the opioid and serotonergic receptors are involved in the antinociception (<LINK REF="REF-Schreiber-1999" TYPE="REFERENCE">Schreiber 1999</LINK>).</P>
<P>With the arrival of atypical antipsychotics, a new class of antipsychotics, fewer extrapyramidal side effects and additional benefits are now available. These new treatments were not included in a meta-analysis of reports on the analgesic effects of antipsychotics performed by <LINK REF="REF-Nix-1998" TYPE="REFERENCE">Nix 1998</LINK>. Therefore, a new meta-analysis is needed to address the question of evidence based pain therapy with antipsychotics.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-08-10 06:05:37 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the analgesic efficacy and adverse effects of antipsychotics in acute or chronic pain in adults.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-11-07 20:44:50 +0000" MODIFIED_BY="Jessica Thomas">
<SELECTION_CRITERIA MODIFIED="2013-11-07 20:44:50 +0000" MODIFIED_BY="Jessica Thomas">
<CRIT_STUDIES MODIFIED="2013-08-21 14:29:56 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) which were double blinded and which investigated the analgesic effects of antipsychotics as monotherapy or add-on treatment in patients with acute or chronic pain, if pain assessment was either the primary or a secondary outcome. Reports were excluded if they were studies which were non-randomised, studies of experimental pain, case reports, clinical observations (open studies) or studies of antipsychotics used to treat pain produced by other drugs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-08-21 14:30:12 +0100" MODIFIED_BY="Jessica Thomas">
<P>Randomised controlled trials (RCTs) of adult patients of either gender who had acute or chronic pain, or both, of all degrees of severity, were included in this review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-11-07 20:44:50 +0000" MODIFIED_BY="Jessica Thomas">
<P>Any form of antipsychotic treatment (at any dose) listed below compared with no treatment, placebo, or other pain relieving treatment (for example non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, anticonvulsants, opiates).</P>
<SUBSECTION>
<HEADING LEVEL="4">Antipsychotic agents or neuroleptics:</HEADING>
<UL>
<LI>amisulpride,</LI>
<LI>amoxapine,</LI>
<LI>chlormethiazole,</LI>
<LI>clopenthixol,</LI>
<LI>chlorpiprazine,</LI>
<LI>chlorpromazine,</LI>
<LI>chlorprothixene,</LI>
<LI>cloxazepine,</LI>
<LI>clozapine,</LI>
<LI>distraneurine,</LI>
<LI>dixyrazine,</LI>
<LI>droperidol</LI>
<LI>chlorpromazine,</LI>
<LI>flupentixol decanoate,</LI>
<LI>fluphenazine,</LI>
<LI>haloperidol,</LI>
<LI>levomepromazine,</LI>
<LI>loxapine,</LI>
<LI>melperone hydrochloride,</LI>
<LI>methotrimeprazine,</LI>
<LI>olanzapine,</LI>
<LI>oxilapine,</LI>
<LI>perphenazine,</LI>
<LI>pimozide,</LI>
<LI>prochlorperazine</LI>
<LI>prothipendyl hydrochloride,</LI>
<LI>quetiapine,</LI>
<LI>risperidone,</LI>
<LI>sulpiride,</LI>
<LI>thioridazine,</LI>
<LI>tiapride,</LI>
<LI>tisercin,</LI>
<LI>trifluoroperazine,</LI>
<LI>ziprsasidone,</LI>
<LI>zotepine,</LI>
<LI>zuclopenthixol.</LI>
</UL>
<P>For the update of this review in January 2013 we included two additional antipsychotics, namely droperidol and prochlorperazine, in our search strategy.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Jessica Thomas">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-08-21 14:32:45 +0100" MODIFIED_BY="Jessica Thomas">
<P>The primary outcome measure for this review was the reduction in pain intensity as measured by a visual analogue scale (VAS), self reported global scale, verbal rating scale, numerical rating scale or categorical pain relief scale, and self reported pain relief. We used the effectiveness measures after the longest reported duration of treatment. We excluded studies which did not quantify pain using a scale. We included patient reported pain data, and excluded trials only reporting physician and carer pain assessment.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Jessica Thomas">
<P>An assessment of the frequency and severity of the commonly expected adverse effects was undertaken. Adverse effects were classified as minor if they were reported by a participant who continued with the medication and completed the trial. A major adverse effect was defined as one that caused the participant to withdraw from the study. Side effect data are recorded in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Additional outcomes</HEADING>
<UL>
<LI>Attrition, the numbers of participants withdrawing before completion of the study in an intervention versus placebo study and an intervention versus other treatment study due to non-compliance, adverse effects or death</LI>
<LI>Measures of satisfaction or patient preference (if reported)</LI>
<LI>Assessment of quality of life (if reported)</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-09-04 14:24:11 +0100" MODIFIED_BY="Jessica Thomas">
<ELECTRONIC_SEARCHES MODIFIED="2013-09-04 14:24:11 +0100" MODIFIED_BY="Anna Hobson">
<P>This search was run for the original review in October 2007 and subsequent searches were run in 2011 and January 2013.</P>
<P>For the identification of studies to be included or considered for this review, the following databases were searched:<BR/>
</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I> (2012, Issue 12);</LI>
<LI>MEDLINE (1966 to January 2013);</LI>
<LI>EMBASE (1989 to January 2013);</LI>
<LI>PsycINFO (1806 to January 2013).</LI>
</UL>
<P>Detailed search strategies were developed for each database searched and the MEDLINE search strategy from the original 2007 search is given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; for other search strategies please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and the search strategies used for the 2013 updated searches can be found in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>. The searches attempted to identify all relevant studies irrespective of language. Non-English papers would be assessed and translated, if necessary, with the assistance of a native speaker.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-07-26 12:30:32 +0100" MODIFIED_BY="Anna Hobson">
<P>We checked reference lists from retrieved trials for additional studies. We also sought relevant studies cited in reviews identified by searching the Cochrane Database of Systematic Reviews (CDSR) and the Database of Abstracts of Reviews and Effectiveness (DARE).</P>
<P>We contacted the corresponding authors of the identified articles and experts in the field for additional studies. Furthermore, we sent letters requesting information about published or unpublished trials to pharmaceutical companies which manufacture antipsychotics (Sanofi-Synthelabo: amisulpride, fluphenazine, sulpiride, tiapride; Lundbeck: chlorprothixene, flupentixol decanoate, melperone, sertindole, zuclopenthixol; Novartis: clozapine, thioridazine; Eli Lilly: olanzapine; AstraZeneca: quetiapine; Janssen-Cilag: haloperidol, pimozide, risperidone; Asta Medica: prothipendyl hydrochloride; Knoll Ltd: zotepine; Pfizer: ziprasidone; Gerot: levomepromazine; UCB-Pharma: dixyrazine).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Jessica Thomas">
<SUBSECTION>
<HEADING LEVEL="3">Study selection</HEADING>
<P>Two review authors (MA and MO) independently screened the titles and abstracts of all the references retrieved by the original search strategy. Two other authors (SS and TS) independently screened the titles and abstracts of all references retrieved by the search strategy for this update. The full text versions of relevant studies were retrieved by BW and were assessed independently by the authors (MA, MO, TS and SS) to determine whether they met the inclusion criteria. Disagreements were resolved by discussion among the four authors mentioned above.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of quality</HEADING>
<P>Trials which met the inclusion criteria were graded independently for methodological quality and assessed for internal validity using the Oxford Quality Scale score (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>):<BR/>
</P>
<UL>
<LI>randomisation (1 = yes; 0 = no);</LI>
<LI>method and description of randomisation (0 = not described; 1 = described and adequate; -1 = described, but not adequate);</LI>
<LI>double blinding (1 = yes; 0 = no);</LI>
<LI>method and description of double blinding (0 = not described; 1 = described and adequate; -1 = described, but not adequate);</LI>
<LI>sufficient information about loss to follow-up (1 = yes; 0 = no).</LI>
</UL>
<P>Each study was allocated a score of between one to five points. Because the inclusion criteria for this review required trials to be randomised, the minimum quality score was one. Higher scores indicated a higher quality of conducting or reporting, or both, of the trial. No trial that scored '0' met the inclusion criteria, the minimum score calculated was two.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>The following data items were extracted from each of the included studies, where available: <B>
<BR/>
</B>
</P>
<UL>
<LI>trial characteristics (methods, duration, interventions);</LI>
<LI>patient characteristics (age, gender, type of pain condition);</LI>
<LI>trial results (patient reported pain intensity or pain relief);</LI>
<LI>adverse effects (major and minor);</LI>
<LI>study withdrawals (due to non-compliance, adverse effects or death);</LI>
<LI>measures of satisfaction or patient preference (if reported); and</LI>
<LI>assessment of quality of life (if reported).</LI>
</UL>
<P>Data were extracted on to a standard form by two review authors working independently. Due to possible carry-over effects, only the first phase of cross-over studies was used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis</HEADING>
<P>Statistical testing of heterogeneity between the trials was carried out by one author (EP) using RevMan Analyses 1.0.3 in Meta-View 4.2.8 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). Results from the trials were combined using a fixed-effect model to calculate relative risks (RR) with 95% confidence intervals (CI) for dichotomous data and weighted mean differences (WMD) for continuous data.</P>
<P>If enough data were available, the number needed to treat to benefit (NNT) was calculated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>The quality of the included trials was used in exploring any significant statistical heterogeneity between them. Cut-off levels for the subgroup analysis values that were used were 'greater or equal to three' or 'less than or equal to two'. <B>
<BR/>
</B>
</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-11-18 09:46:09 +0000" MODIFIED_BY="Jessica Thomas">
<STUDY_DESCRIPTION MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="Jessica Thomas">
<SUBSECTION>
<HEADING LEVEL="3">Study selection</HEADING>
<P>The search for this update (from October 2007 to January 2013) resulted in 2083 hits. After screening of the titles and abstracts five potentially relevant studies were identified. Unfortunately, these studies had to be excluded because of the following reasons.</P>
<UL>
<LI>The study by Hill et al (<LINK REF="STD-Hill-2008" TYPE="STUDY">Hill 2008</LINK>) compared the efficacy of the antipsychotic to another antipsychotic (that is droperidol).</LI>
<LI>The study by Friedman et al (<LINK REF="STD-Friedman-2008" TYPE="STUDY">Friedman 2008</LINK>) compared the efficacy of the antipsychotic to metoclopramide.</LI>
<LI>The study by Miller et al (<LINK REF="STD-Miller-2009" TYPE="STUDY">Miller 2009</LINK>) compared the efficacy of the antipsychotic to octreotide.</LI>
<LI>The study by Kostic et al (<LINK REF="STD-Kostic-2010" TYPE="STUDY">Kostic 2010</LINK>) compared a combination of prochlorperazin with diphenhydramine to sumatriptan.</LI>
<LI>The study by Potvin et al (<LINK REF="STD-Potvin-2012" TYPE="STUDY">Potvin 2012</LINK>) did not use pain as the primary outcome parameter.</LI>
</UL>
<P>The original search strategy, run in October 2007, resulted in 1908 hits. After screening of the titles and abstracts, 56 potentially relevant studies were identified. Forty-one studies were excluded (<I>see </I>'<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table). In short, 39 studies did not meet the quality criteria as assessed by the Oxford Quality Scale. Two high-quality studies (<LINK REF="STD-Brousseau-2004" TYPE="STUDY">Brousseau 2004</LINK>; <LINK REF="STD-Weaver-2004" TYPE="STUDY">Weaver 2004</LINK>;) were excluded because they reported the efficacy of an antipsychotic on headache in children and adolescents (<LINK REF="STD-Brousseau-2004" TYPE="STUDY">Brousseau 2004</LINK>) and compared two antipsychotics (droperidol vs. prochlorperazine) without the use of a placebo (<LINK REF="STD-Weaver-2004" TYPE="STUDY">Weaver 2004</LINK>). Hence, 15 studies were considered for inclusion in this review. Two of these studies could not be assessed because a translation into English was not available (<LINK REF="STD-Govorin-1990" TYPE="STUDY">Govorin 1990</LINK>; <LINK REF="STD-Lepola-1984" TYPE="STUDY">Lepola 1984</LINK>). For one further study the authors could not be identified, and it was therefore excluded (<LINK REF="STD-Anon-1986" TYPE="STUDY">Anon 1986</LINK>).</P>
<P>Overall 12 RCTs of nine different antipsychotics were considered eligible (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>; <LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>; <LINK REF="STD-Ginsberg-1983" TYPE="STUDY">Ginsberg 1983</LINK>; <LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>; <LINK REF="STD-Honkaniemi-2006" TYPE="STUDY">Honkaniemi 2006</LINK>; <LINK REF="STD-Johnston-1972" TYPE="STUDY">Johnston 1972</LINK>; <LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK>; <LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>; <LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>; Richman 2002a; <LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>; <LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>) (n = 772) for inclusion in the review, please see the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table for full details of each included study. All included studies were clinic based and single centered, with one (<LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>) explicitly stating the inclusion of outpatients. They were conducted at the departments for neurology (n = 4) (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>; <LINK REF="STD-Honkaniemi-2006" TYPE="STUDY">Honkaniemi 2006</LINK>; <LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>; <LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>), anaesthesiology (n = 2) (<LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>; <LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK>), psychiatry (n = 1) (<LINK REF="STD-Zitman-1992" TYPE="STUDY">Zitman 1992</LINK>), neurosurgery (n = 1) (<LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>), oncology (n = 1) (<LINK REF="STD-Johnston-1972" TYPE="STUDY">Johnston 1972</LINK>) and the emergency department (n = 2) (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>; Richman 2002a). The site of the remaining study (<LINK REF="STD-Ginsberg-1983" TYPE="STUDY">Ginsberg 1983</LINK>) could not be specified. The sample size ranged from 29 to 316 participants. Most trials were limited by their small sample size. Only one trial included more than 200 participants (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>). Eight studies were placebo-controlled and were considered for quantitative analysis. Data from six studies could not be included in the quantitative analysis because of the following reasons.<BR/>
</P>
<UL>
<LI>Two studies compared the efficacy of the antipsychotic to an opioid (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>) or a selective serotonin reuptake inhibitor (SSRI) (<LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>).</LI>
<LI>One study only reported on the occurrence of headaches following an intervention (<LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>).</LI>
<LI>One study did not provide information about the duration of treatment (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>).</LI>
<LI>The work of <LINK REF="STD-Johnston-1972" TYPE="STUDY">Johnston 1972</LINK> fulfilled the inclusion criteria, but due to missing data on variability, the study could not be included in the final analyses. Similarly, the study by <LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK> had to be excluded due to missing data on the mean and variability of the selected outcome variables.</LI>
</UL>
<P>Risk of bias is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for each included study.</P>
<P>For the meta-analyses, the primary outcome variable was the difference in mean in the treatment and placebo groups (after - baseline) and therefore reflected how much the VAS score could be reduced by the treatment. Additionally, the meta-analysis was performed for the mean outcome VAS score following treatment in both groups. For the dichotomous event, feeling pain or no pain after treatment, the RR indicated the chance of having pain after receiving the intervention, an absolute risk reduction (ARR) &lt; 1 means that the chance of having pain after the intervention is smaller in the treatment group than in the control group. The study authors were contacted to provide missing data, if necessary. Standard errors were converted into standard deviations. If the standard deviation of the difference in mean was not given, but the standard deviation from baseline and after treatment was given, imputation strategies were used (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If values for the mean or standard deviation were not mentioned in the text, but were displayed in a figure, values were taken from the figure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study design</HEADING>
<P>Nine of the included studies had a parallel design and three had a cross-over design. Some trials had more than two arms and made more than one comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>Pain was patient reported in 12 trials. In one study information on pain was provided by the patients' weekly ratings (<LINK REF="STD-Johnston-1972" TYPE="STUDY">Johnston 1972</LINK>). In six trials pain was reported using a pain diary (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>; <LINK REF="STD-Ginsberg-1983" TYPE="STUDY">Ginsberg 1983</LINK>; <LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>; <LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>; <LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>; <LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>). Three trials documented the analgesic requirements of the patients on a numeric VAS (<LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK>; Richman 2002a; <LINK REF="STD-Honkaniemi-2006" TYPE="STUDY">Honkaniemi 2006</LINK>). Two trials simply reported on the mere occurrence of pain (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>; <LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study methods</HEADING>
<P>All 12 included studies were conducted in a double-blind fashion. Eight trials compared an antipsychotic or a combination of analgesic and antipsychotic to placebo and three studies compared an antipsychotic or a combination of analgesic and antipsychotic to treatment with an active compound (that is antidepressants, antiepileptics or analgesics).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antipsychotics</HEADING>
<P>Trials using the following antipsychotics were found:<BR/>
</P>
<UL>
<LI>Five with tricyclic antipsychotics (flupentixol, fluphenazine, thioridazine, levomepromazine);</LI>
<LI>four with butyrophenones (droperidol, haloperidol);</LI>
<LI>three with benzamides (sulpiride, tiapride, pimozide).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Patient conditions</HEADING>
<P>The underlying conditions studied were as follows:<BR/>
</P>
<UL>
<LI>somatoform pain disorder, one study;</LI>
<LI>post-herpetic neuralgia, one study;</LI>
<LI>acute (migraine) headache, two studies;</LI>
<LI>pain in terminal cancer, one study;</LI>
<LI>postoperative pain, one study;</LI>
<LI>trigeminal neuralgia, one study;</LI>
<LI>acute rheumatic pain, one study;</LI>
<LI>chronic tension-type headache, two studies;</LI>
<LI>post-rachiocentesis headache, one study; and</LI>
<LI>acute myocardial infarction, one study.</LI>
</UL>
<P>
<BR/>Details of these eligible reports are provided in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-08-21 14:51:37 +0100" MODIFIED_BY="Jessica Thomas">
<P>Each study was scored independently for quality by two of the review authors (MA and MO) using the three-item Oxford Quality Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The scores for individual trials are reported in the notes section of the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table. The median quality score for the placebo-controlled studies was three (all trials scored three), and for the active control studies it was also three (range three to four).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-11-18 09:46:09 +0000" MODIFIED_BY="Jessica Thomas">
<P>Overall 12 RCTs of nine different antipsychotics were considered eligible (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>; <LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>; <LINK REF="STD-Ginsberg-1983" TYPE="STUDY">Ginsberg 1983</LINK>; <LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>; <LINK REF="STD-Honkaniemi-2006" TYPE="STUDY">Honkaniemi 2006</LINK>; <LINK REF="STD-Johnston-1972" TYPE="STUDY">Johnston 1972</LINK>; <LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK>; <LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>; <LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>; Richman 2002a; <LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>; <LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>) (total n = 743) for inclusion in the review. Forty studies were excluded and are listed in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
<SUBSECTION>
<HEADING LEVEL="3">Tricyclic antipsychotics</HEADING>
<P>Four trials (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>; <LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>; <LINK REF="STD-Johnston-1972" TYPE="STUDY">Johnston 1972</LINK>; <LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>), with a total of 449 participants, studied the effects of tricyclic antipsychotics in different painful disorders. These trials studied the effect of tricyclic antipsychotics in:</P>
<OL>
<LI>pain following myocardial infarction (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>),</LI>
<LI>pain due to terminal cancer (<LINK REF="STD-Johnston-1972" TYPE="STUDY">Johnston 1972</LINK>),</LI>
<LI>somatoform pain disorder (<LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>), and</LI>
<LI>post-herpetic neuralgias (<LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>).</LI>
</OL>
<P>The description of the study results is given below.</P>
<SUBSECTION>
<HEADING LEVEL="4">Tricyclic antipsychotics versus placebo</HEADING>
<P>One study indicated only a small positive effect of 75 mg thioridazine daily compared to placebo concerning global improvement and pain in terminal cancer patients (P &lt; 0.1) (<LINK REF="STD-Johnston-1972" TYPE="STUDY">Johnston 1972</LINK>). The study of Graff-Radford et al had four arms (amitriptyline, amitriptyline + fluphenazine, fluphenazine, and placebo). For quantitative analysis we only included data from the fluphenazine and the placebo arms (<LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tricyclic antipsychotics versus other active treatment</HEADING>
<P>Three studies compared tricyclic antipsychotics to other active treatments, including amitriptyline (a tricyclic antidepressant) (<LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>; <LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>) and pethidine (an opioid) (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>).</P>
<P>Administration of levomepromazine proved to significantly reduce the recurrence of pain within the first 72 hours after an acute myocardial infarction compared to treatment with pethidine (P &lt; 0.05) (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>). In the case of post-herpetic neuralgia the decrease of pain in patients receiving fluphenazine did not reach statistical significance. Combination of the antipsychotic with a tricyclic antidepressant (that is amitriptyline) and comparison with treatment with amitriptyline alone failed to produce a significant advantage using fluphenazine: mean difference (MD) 0.54 (95% CI -1.49 to 2.57) (<LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>). In another study, patients with a somatoform pain disorder receiving 75 mg amitriptyline or 75 mg amitriptyline plus 3 mg flupentixol experienced significantly less pain during the treatment. Yet, the comparison of pain reduction in both groups did not reveal a statistically significant MD (MD -0.60, 95% CI -2.10 to 0.90) (<LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Butyrophenones</HEADING>
<P>Three placebo-controlled RCTs (<LINK REF="STD-Honkaniemi-2006" TYPE="STUDY">Honkaniemi 2006</LINK>; <LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK>; Richman 2002a), with a total of 110 participants, studied the effects of butyrophenones on postoperative pain (<LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK>) and acute migraine headache (<LINK REF="STD-Honkaniemi-2006" TYPE="STUDY">Honkaniemi 2006</LINK>; Richman 2002a).</P>
<P>In the case of postoperative pain two different dosages of haloperidol (5 and 10 mg orally) were compared against placebo as premedication before major abdominal surgery (<LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK>). VAS scores for pain at 24 hours after surgery did not differ significantly between the three groups of participants. Only a significant reduction of postoperative emesis was found in both groups treated with haloperidol. In contrast, treatment of acute migraine headache with 5 mg intravenous haloperidol was shown to be significantly superior to placebo (MD -4.05, 95% CI -5.61 to -2.49) (<LINK REF="STD-Honkaniemi-2006" TYPE="STUDY">Honkaniemi 2006</LINK>). Another study on acute migraine compared 2.5mg intramuscular droperidol with 1.5mg/kg meperidine and failed to detect a significant difference regarding post-treatment pain intensity (VAS) (47 vs. 37 mm, p=.033) (Richman 2002a).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Benzamides</HEADING>
<P>Five double-blind trials with a total of 240 participants, two of them placebo-controlled (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>; <LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>), studied the effects of benzamides on different types of headache (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>; <LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>; <LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>), trigeminal neuralgia (<LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>) and acute rheumatic pain (<LINK REF="STD-Ginsberg-1983" TYPE="STUDY">Ginsberg 1983</LINK>).</P>
<P>In the case of chronic tension-type headache tiapride was compared with placebo (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>) and sulpiride was compared with another active component, that is paroxetine an SSRI (<LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>). It seemed noteworthy that five participants in the group receiving sulpiride dropped out during the study due to intolerable side effects (<LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>), see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for further details.</P>
<SUBSECTION>
<HEADING LEVEL="4">Benzamides versus placebo</HEADING>
<P>The effect of intravenous tiapride (dosage 200 mg) following rachiocentesis was studied in a small sample (n = 30) (<LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>). The authors only reported the percentage of patients who experienced pain within 48 hours after rachiocentesis, but did not provide any further details (for example pain severity or associated symptoms). When compared to the placebo, tiapride led to a reduction in the occurrence of headaches. In detail, 86.7% of patients who had received tiapride before the rachiocentesis and 46.6% of patients who had received placebo did not report headaches within 48 hours following the procedure. These results were statistically significant (P &lt; 0.01).</P>
<P>An Italian group reported on the efficacy of 300 mg tiapride administered orally on chronic tension-type headache, but failed to provide any information on the duration of the treatment conducted in the study (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>). Forty per cent of the patients treated with tiapride were complete responders compared to no responders with placebo (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Benzamides versus other active treatment</HEADING>
<P>Sulpiride (400 mg daily) and paroxetine (30 mg daily), an SSRI, were compared in a group of 50 patients suffering from chronic tension-type headache in a cross-over conditional-response design (<LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>). Each treatment period lasted eight weeks. Patients recorded their pain in headache diaries. Total pain scores differed significantly between groups (P = 0.03) favouring treatment with the antipsychotic.</P>
<P>Pimozide (12 mg daily) and carbamazepine (1200 mg daily), antiepileptic drugs established in the treatment of neuralgic pain, were tested in the treatment of pain due to trigeminal neuralgia in 48 participants, using a cross-over design (<LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>). During both treatment phases pimozide proved to be superior to carbamazepine regarding total trigeminal neuralgia pain scores (P &lt; 0.01) (MD -4.11, 95% CI -8.08 to -0.14).</P>
<P>In the case of acute rheumatic pain tiapride (100 mg daily) and glafenine (200 mg daily), an anthranilic acid derivative with analgesic properties, were compared during a 14-day double-blind trial (<LINK REF="STD-Ginsberg-1983" TYPE="STUDY">Ginsberg 1983</LINK>). Tiapride was significantly superior to glafenine regarding the time delay until the disappearance of the pain (P &lt; 0.05). Concerning pain reduction there was a trend favouring the antipsychotic (RR 0.73, 95% CI 0.37 to 1.44), though it failed to show statistical significance. A separate analysis according to the sex of patients did not reveal any significant differences (<LINK REF="STD-Ginsberg-1983" TYPE="STUDY">Ginsberg 1983</LINK>).</P>
<P>Five of these trials permitted a quantitative analysis of the study data according to our protocol. The results of these analyses are available in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> and <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="Jessica Thomas">
<P>This systematic review revealed a small number (n = 12) of small-sized clinical trials (total n = 772) that compared the analgesic effects of antipsychotics to placebo or active compounds in a randomised double-blind fashion.</P>
<P>There are some preclinical studies in humans that link the dopaminergic system with pain. In one study an inverse correlation of pain threshold and the response criterion with the D<SUB>2</SUB>/D<SUB>3</SUB> binding potential in the right putamen was found (<LINK REF="REF-Pertovaara-2004" TYPE="REFERENCE">Pertovaara 2004</LINK>). This finding is supported by a number of animal studies which have suggested that dopamine is involved in the regulation of nociception. However, the data are contradictory as dopamine agonists have been shown to produce either antinociception (<LINK REF="REF-Shimizu-2004" TYPE="REFERENCE">Shimizu 2004</LINK>) or hyperalgesia (<LINK REF="REF-Paalzow-1992" TYPE="REFERENCE">Paalzow 1992</LINK>).</P>
<P>It appears reasonable to further investigate the analgesic effect of various antipsychotics in different pain syndromes. Thus, we describe the effects of different antipsychotics in the following painful conditions.</P>
<SUBSECTION>
<HEADING LEVEL="2">Headaches</HEADING>
<P>The effects of antipsychotics have been studied in the treatment of acute migraine headache (<LINK REF="STD-Honkaniemi-2006" TYPE="STUDY">Honkaniemi 2006</LINK>; Richman 2002a), chronic tension-type headache (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>; <LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>) and headaches following rachiocentesis (<LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>) using randomised double-blind designs. All but one trial (Richman 2002a) demonstrated statistically significant positive results for antipsychotics, that is haloperidol, sulpirid and tiaprid. It seems noteworthy that administration of tiaprid did not lead to a greater reduction of headache intensity, but led to a faster amelioration of headache following rachiocentesis (<LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Neuralgic pain</HEADING>
<P>Treatment of patients with neuralgic pain (post-herpetic neuralgia (<LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>) and trigeminal neuralgia (<LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>)) delivered both positive and negative results. Fluphenazine, used in the case of post-herpetic neuralgia, did not prove to be superior to amitriptyline, a tricyclic antidepressant (<LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>). On the other hand, a study with patients suffering from trigeminal neuralgia appeared to show that pimozide led to a significantly greater reduction of pain in a double-blind cross-over study (<LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Other painful conditions</HEADING>
<P>The effects on several other painful conditions have been studied in double-blind RCTs. We could only identify a single study for each condition, which met our inclusion criteria. This is one of the limitations of the data presented here. In summary, we can say that only one study reported a statistically significant positive effect on pain, that is pain following an acute myocardial infarction (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>). Intriguingly, that study turned out to hold the largest sample (n = 316) of all studies included. Trials on somatoform pain disorders (<LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>), postoperative pain (<LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK>) and acute rheumatic pain (<LINK REF="STD-Ginsberg-1983" TYPE="STUDY">Ginsberg 1983</LINK>) failed to deliver significant results favouring the treatment with antipsychotics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Antipsychotics and acute pain</HEADING>
<P>Four of six studies on acute painful conditions that were reviewed here (<LINK REF="STD-Ginsberg-1983" TYPE="STUDY">Ginsberg 1983</LINK>; <LINK REF="STD-Judkins-1982" TYPE="STUDY">Judkins 1982</LINK>; Richman 2002a; <LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>) did not find significant positive results for antipsychotics concerning reduction of pain intensity. One study (<LINK REF="STD-Davidsen-1979" TYPE="STUDY">Davidsen 1979</LINK>), using a large sample of patients, reported a statistically significant reduction of pain after an acute myocardial infarction. The data of Honkaniemi and colleagues demonstrated an excellent response of acute migraine headache to the administration of haloperidol (<LINK REF="STD-Honkaniemi-2006" TYPE="STUDY">Honkaniemi 2006</LINK>). In addition, after the administration of tiaprid post-rachiocentesis headache disappeared more quickly when compared to placebo, although pain reduction was not greater than in patients who received placebo (<LINK REF="STD-Roux-1983" TYPE="STUDY">Roux 1983</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Antipsychotics and chronic pain</HEADING>
<P>Six studies included in this review focused on the management of chronic pain conditions. In the case of chronic tension-type headaches two studies reported beneficial effects for patients treated with antipsychotics when compared to placebo or another active component (<LINK REF="STD-Bussone-1980" TYPE="STUDY">Bussone 1980</LINK>; <LINK REF="STD-Langemark-1994" TYPE="STUDY">Langemark 1994</LINK>). Results concerning neuralgic pain turned out to be both negative (<LINK REF="STD-Graff_x002d_Radford-2000" TYPE="STUDY">Graff-Radford 2000</LINK>) and positive (<LINK REF="STD-Lechin-1989" TYPE="STUDY">Lechin 1989</LINK>). In the latter study the antipsychotic was more efficient than carbamazepine, a well-established drug in the treatment of neuralgias. Treatment of a somatoform (that is physical symptoms that mimic disease or injury for which there is no identifiable physical cause) pain disorder with flupentixol (<LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>) and pain in terminal cancer patients with thioridazine (<LINK REF="STD-Johnston-1972" TYPE="STUDY">Johnston 1972</LINK>) was not reported to be superior to placebo or another treatment (<LINK REF="STD-Zitman-1991" TYPE="STUDY">Zitman 1991</LINK>).</P>
<P>Summarising the results of all 11 included RCTs we found a positive effect in painful conditions in six trials, whereas five trials failed to report any analgesic effect of the antipsychotics studied. Five trials proved eligible for a meta-analysis. We next set out to perform quantitative analyses of studies on acute (n = 2) and chronic pain (n = 3) separately, but this does not seem reasonable to us due to the small number and tremendous clinical heterogeneity of the studies. In addition, the data reviewed here have further limitations as most trials studied small samples of patients and only one included more than 200 participants. Moreover, pain assessment varied among the different protocols. Some studies only reported on the (re-)occurrence of pain, which is, from our point of view, not sufficient to assess the whole effect on painful states.</P>
<P>Thus, in the present review the evidence of analgesic properties of antipsychotics can only be described relying on each single study. From a clinical point of view further research on analgesic properties of antipsychotics is indicated in more RCTs. Since nowadays atypical antipsychotics, which are known to produce lesser extrapyramidal side effects, are available, this new group of antipsychotics clearly needs to be studied regarding their analgesic potency.</P>
<P>In this update we also added antipsychotics (that is prochlorperazine and droperidol) to our search strategy. Nevertheless we could not include any new studies. One of the excluded studies (<LINK REF="STD-Hill-2008" TYPE="STUDY">Hill 2008</LINK>) concluded that olanzapine, a newer atypical antipsychotic, was equally potent to droperidol, an older antipsychotic, to relieve headaches. This finding should encourage researchers to further study the efficacy of newer antipsychotic agents in the treatment of pain disorders.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Jessica Thomas">
<IMPLICATIONS_PRACTICE MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Jessica Thomas">
<P>Antipsychotics could be used as add-on therapy in the treatment of painful conditions, as a possibility for treatment-resistant pain. Adverse effects of typical antipsychotics, especially the extrapyramidal and sedating effects, have to be considered in the decision algorithm for the use of antipsychotics in painful conditions. Nevertheless, the significance of these results is limited due to the heterogeneity of the included studies.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-08-21 15:02:10 +0100" MODIFIED_BY="Anna Hobson">
<P>The results for antipsychotics in the treatment of different painful conditions are heterogeneous and most sample sizes in the reviewed randomised double-blind studies are small. However, further studies are warranted on atypical antipsychotics with fewer side effects than the classical antipsychotics, in larger double-blind placebo-controlled studies that include standardised pain assessment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Tiina Saarto for data extraction and translation of manuscripts.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-08-21 15:02:17 +0100" MODIFIED_BY="Anna Hobson">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Stefan Seidel: final draft of the manuscript.<BR/>Thomas Sycha, Martin Aigner, Michael Ossege: search strategy and protocol, conceived and planned the review, quality assessment of identified studies, revision of the manuscript.<BR/>Elisabeth Pernicka: statistics.<BR/>Brigitte Wildner: search strategy, delivery of printed versions.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2015-11-27 12:20:35 +0000" MODIFIED_BY="Anna Hobson">
<P>This review was first published in Issue 4, 2008. Citation: Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD004844. DOI: 10.1002/14651858.CD004844.pub2.</P>
<P>At November 2015, the authors and editors have agreed to split this review into separate titles which will serve to update and replace the original. The planned titles are for antipsychotics for headache and migraine, and neuropathic pain. For more information, please contact the PaPaS CRG.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="Jessica Thomas">
<STUDIES MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="Jessica Thomas">
<INCLUDED_STUDIES MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="Jessica Thomas">
<STUDY DATA_SOURCE="PUB" ID="STD-Bussone-1980" NAME="Bussone 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bussone G, Boiardi A, Merati B, Recchia M, Salom Pedemonti D, et al</AU>
<TI>Tiapride in the treatment of chronic headache</TI>
<SO>Rivista de Patologia Nervosa e Mentale</SO>
<YR>1981</YR>
<VL>101</VL>
<PG>247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidsen-1979" NAME="Davidsen 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidsen O, Lindeneg O, Walsh M</AU>
<TI>Analgesic treatment with levomepromazine in acute myocardial infarction. A randomized clinical trial</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1979</YR>
<VL>205</VL>
<PG>191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ginsberg-1983" NAME="Ginsberg 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ginsberg F, Bourguignon RP, Smets P, Famaey JP</AU>
<TI>Tiapride versus glafenine: a double-blind comparative study in the management of acute rheumatic pain</TI>
<SO>Current Medical and Research Opinion</SO>
<YR>1983</YR>
<VL>8</VL>
<PG>562-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graff_x002d_Radford-2000" NAME="Graff-Radford 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graff-Radford SB, Shaw LR, Naliboff BN</AU>
<TI>Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>188-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Honkaniemi-2006" NAME="Honkaniemi 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S</AU>
<TI>Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study</TI>
<SO>Headache</SO>
<YR>2006</YR>
<VL>46</VL>
<PG>781-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnston-1972" NAME="Johnston 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnston B</AU>
<TI>Relief of mixed anxiety-depression in terminal cancer patients. Effect of thioridazine</TI>
<SO>New York State Journal of Medicine</SO>
<YR>1972</YR>
<VL>72</VL>
<PG>2315-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Judkins-1982" NAME="Judkins 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Judkins KC, Harmer M</AU>
<TI>Haloperidol as an adjunct analgesic in the management of postoperative pain</TI>
<SO>Anaesthesia</SO>
<YR>1982</YR>
<VL>37</VL>
<PG>1118-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langemark-1994" NAME="Langemark 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langemark M, Olesen J</AU>
<TI>Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial</TI>
<SO>Headache</SO>
<YR>1994</YR>
<VL>34</VL>
<PG>20-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lechin-1989" NAME="Lechin 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lechin F, van der Dijs B, Lechin ME, Amat J, Lechin AE, Cabrera A, et al</AU>
<TI>Pimozide therapy for trigeminal neuralgia</TI>
<SO>Archives of Neurology</SO>
<YR>1989</YR>
<VL>46</VL>
<PG>960-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richman-2002" MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="Stefan Seidel" NAME="Richman 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="Stefan Seidel" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richman PB, Allegra J, Eskin B, Doran J, Reischel U, Kaiafas C, et al</AU>
<TI>A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>39-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roux-1983" NAME="Roux 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roux FX, Mallet A, Meresse S</AU>
<TI>Prevention of headache following lumbar puncture. A controlled double blind trial of the effectiveness of intravenous tiapride</TI>
<SO>La Semaine de Hôpitaux</SO>
<YR>1982</YR>
<VL>59</VL>
<PG>319-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zitman-1991" MODIFIED="2008-08-07 17:13:43 +0100" MODIFIED_BY="Jessica Thomas" NAME="Zitman 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-08-07 17:13:43 +0100" MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zitman FG, Linssen AC, Edelbroek PM, Van Kempen GM</AU>
<TI>Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder?</TI>
<SO>Pain</SO>
<YR>1991</YR>
<VL>47</VL>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="Jessica Thomas">
<STUDY DATA_SOURCE="PUB" ID="STD-Adeloye-1971" NAME="Adeloye 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adeloye A</AU>
<TI>Clinical trial of fluphenazine in the post-concussional syndrome</TI>
<SO>Practitioner</SO>
<YR>1971</YR>
<VL>206</VL>
<PG>571-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anon-1986" NAME="Anon 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>Amitriptyline and fluphenazine for painful diabetic neuropathy</TI>
<SO>JAMA</SO>
<YR>1986</YR>
<VL>256</VL>
<PG>712-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbier-1989" NAME="Barbier 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbier JP, Dorf G, Gordin J, Krainik F, Neveu D, Parlier H, et al</AU>
<TI>Effect of a buzepide metiodide-haloperidol combination in treating functional intestinal disorders. Randomized double-blind controlled versus placebo study</TI>
<TO>Effet de l´association métiodure de buzepide-haloperidol dans le traitement des troubles fonctionnels intestinaux</TO>
<SO>Annales de Gastroenterologie et d Hepatologie</SO>
<YR>1989</YR>
<VL>25</VL>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brousseau-2004" NAME="Brousseau 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brousseau DC, Duffy SJ, Anderson AC, Linakis JG</AU>
<TI>Treatment of pediatric migraine headaches: A randomized, double-blind trial of prochlorperazine versus ketorolac</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2004</YR>
<VL>43</VL>
<PG>256-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerbo-1982a" NAME="Cerbo 1982a" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerbo R, Casacchia M, Boni B, Corona R</AU>
<TI>Double-blind trial of tiapride versus placebo in patients with sub-perennial idiopathic headache</TI>
<SO>La Semaine de Hôpitaux</SO>
<YR>1982</YR>
<VL>58</VL>
<PG>2839-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerbo-1982b" NAME="Cerbo 1982b" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerbo R, Casacchia M, Boni B, Corona R, Papola S, de Lena C</AU>
<TI>Double-blind study of tiapride and placebo in patients with subcontinuous essential headache</TI>
<SO>Rivista di Neurologia</SO>
<YR>1982</YR>
<VL>52</VL>
<PG>51-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clavel-1980" NAME="Clavel 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clavel M, Pommatau E</AU>
<TI>Analgesic effects of tiapride in man. A double-blind comparative clinical trial against placebo</TI>
<SO>La Semaine de Hôpitaux</SO>
<YR>1980</YR>
<VL>56</VL>
<PG>430-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clavel-1984" NAME="Clavel 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clavel M, Pommatau E</AU>
<TI>Controlled study of the analgesic efficacy of 2 drugs: tiapride versus aspirin</TI>
<SO>La Semaine de Hôpitaux</SO>
<YR>1984</YR>
<VL>60</VL>
<PG>565-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corazza-1996" NAME="Corazza 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corazza GR, Biagi F, Albano O, Porro GB, Cheli R, Mazzacca G, et al</AU>
<TI>Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial</TI>
<SO>The Italian Journal of Gastroenterology</SO>
<YR>1996</YR>
<VL>28</VL>
<PG>317-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-2008" MODIFIED="2013-08-10 10:45:14 +0100" MODIFIED_BY="Stefan Seidel" NAME="Friedman 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-08-10 10:45:14 +0100" MODIFIED_BY="Stefan Seidel" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedman BW, Esses D, Solorzano C, Dua N, Greenwald P, Radulescu R, et al</AU>
<TI>A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2008</YR>
<VL>52</VL>
<PG>399-406</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Girard-1970" NAME="Girard 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Girard M, Sambin P, Trepo C</AU>
<TI>Clinical trial of sulpiride in ulcerous disease</TI>
<SO>Therapeutique</SO>
<YR>1970</YR>
<VL>46</VL>
<PG>639-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez_x002d_Perez-1985" NAME="Gomez-Perez 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez-Perez FJ, Rull JA, Dies H, Rodriquez-Rivera JG, Gonzalez-Barranco J, Lozano-Castaneda O</AU>
<TI>Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study</TI>
<SO>Pain</SO>
<YR>1985</YR>
<VL>23</VL>
<PG>395-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez_x002d_Perez-1996" NAME="Gomez-Perez 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez-Perez FJ, Choza R, Rios JM, Reza A, Huerta E, Aguilar CA, et al</AU>
<TI>Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy</TI>
<SO>Archives of Medical Research</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>4</NO>
<PG>525-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grillage-1986" NAME="Grillage 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grillage M</AU>
<TI>Neurotic depression accompanied by somatic symptoms: a double-blind comparison of flupenthixol and diazepam in general practice</TI>
<SO>Pharmatherapeutica</SO>
<YR>1986</YR>
<VL>4</VL>
<PG>561-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hakkarainen-1973" NAME="Hakkarainen 1973" YEAR="19731">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakkarainen H, Viukari M</AU>
<TI>Sulpiride in the treatment of migraine, tension headache and associated psychosomatic disorders</TI>
<SO>Duodecim</SO>
<YR>1973</YR>
<VL>89</VL>
<PG>1504-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hakkarainen-1977" NAME="Hakkarainen 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakkarainen H</AU>
<TI>Fluphenazine for tension headache; double-blind study</TI>
<SO>Headache</SO>
<YR>1977</YR>
<VL>17</VL>
<PG>216-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-2008" MODIFIED="2013-08-10 10:46:14 +0100" MODIFIED_BY="[Empty name]" NAME="Hill 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-08-10 10:46:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill CH, Miner JR, Martel ML</AU>
<TI>Olanzapine versus droperidol for the treatment of primary headache in the emergency department</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>806-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jokinen-1984" NAME="Jokinen 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jokinen K, Koskinen T, Selonen R</AU>
<TI>Flupenthixol versus diazepam in the treatment of psychosomatic disorders: a double-blind, multi-centre trial in general practice</TI>
<SO>Pharmatherapeutica</SO>
<YR>1984</YR>
<VL>3</VL>
<PG>573-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kostic-2010" MODIFIED="2013-08-10 10:47:20 +0100" MODIFIED_BY="[Empty name]" NAME="Kostic 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-08-10 10:47:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT</AU>
<TI>A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2010</YR>
<VL>56</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lam-1978" NAME="Lam 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lam SK, Lam KC, Lai CL, Yeung CK, Yam LY, Wong WS</AU>
<TI>Treatment of duodenal ulcers with antacid mixtures and sulpiride. A double-blind controlled study</TI>
<SO>La Semaine de Hôpitaux</SO>
<YR>1978</YR>
<VL>54</VL>
<PG>1404-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lancaster_x002d_Smith-1982" NAME="Lancaster-Smith 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lancaster-Smith MJ, Prout BJ, Pinto T, Anderson JA, Schiff AA</AU>
<TI>Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1982</YR>
<VL>66</VL>
<PG>33-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Derff-1982" NAME="Le Derff 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Derff H</AU>
<TI>Trial of tiapride as an analgesic in cancer patients</TI>
<SO>La Semaine de Hôpitaux</SO>
<YR>1982</YR>
<VL>58</VL>
<PG>1708-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobera-1980" NAME="Lobera 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobera A, Avril A, Bonichon F, Maree D</AU>
<TI>Randomized trial with tiapride in post-operative care</TI>
<SO>Annales de Chirurgie</SO>
<YR>1981</YR>
<VL>35</VL>
<PG>62-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macarri-1992" NAME="Macarri 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macarri G, Biasi L, Brunelli E, Marucci L, Svegliati Baroni G</AU>
<TI>L-sulpiride versus metoclopramide in functional dyspepsia: a randomized double-blind study</TI>
<SO>Minerva Medica</SO>
<YR>1992</YR>
<VL>83</VL>
<PG>295-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maina-2002" NAME="Maina 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maina G, Vitalucci A, Gandolfo S, Bogetto F</AU>
<TI>Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1984" NAME="Martin 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin MR, Schiff AA</AU>
<TI>Fluphenazine/nortriptyline in the irritable bladder syndrome. A double-blind placebo controlled study</TI>
<SO>British Journal of Urology</SO>
<YR>1984</YR>
<VL>56</VL>
<PG>178-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menault-1981" NAME="Menault 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menault F</AU>
<TI>Maintenance therapy in cranio-facial pain: a controlled trial with tiapride</TI>
<SO>La Semaine de Hôpitaux</SO>
<YR>1981</YR>
<VL>57</VL>
<PG>1015-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendel-1986" NAME="Mendel 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendel CM, Klein RF, Chappell DA, Dere WH, Gertz BJ, Karam JH, et al</AU>
<TI>A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy</TI>
<SO>JAMA</SO>
<YR>1986</YR>
<VL>255</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mereto-1974" NAME="Mereto 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mereto GC</AU>
<TI>Double-blind controlled trial on treatment of psychosomatic syndromes by a new tranquilizer combination</TI>
<SO>Minerva Medica</SO>
<YR>1974</YR>
<VL>65</VL>
<PG>923-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2009" MODIFIED="2013-08-10 10:50:32 +0100" MODIFIED_BY="Stefan Seidel" NAME="Miller 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-08-10 10:50:32 +0100" MODIFIED_BY="Stefan Seidel" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller MA, Levsky ME, Enslow W, Rosin A</AU>
<TI>Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>160-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagliarini-1968" NAME="Pagliarini 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pagliarini G, Pollazzon G, Ridolfi C, Rizzi R, Vacondio L</AU>
<TI>Clinico-statistical pluricentral study of postoperative pain</TI>
<SO>Minerva Anestesiologica</SO>
<YR>1986</YR>
<VL>34</VL>
<PG>626-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pisani-1984" NAME="Pisani 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pisani RA, Lazzari R, Arzilli A, Franzese A, Carfagna L, Cerbo R, et al</AU>
<TI>Clinical findings and test results in a group of patients with headaches treated with amitriptyline as compared with perphenazine</TI>
<SO>La Clinica Terapeutica</SO>
<YR>1985</YR>
<VL>113</VL>
<PG>117-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potvin-2012" MODIFIED="2013-08-10 10:51:23 +0100" MODIFIED_BY="Stefan Seidel" NAME="Potvin 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-10 10:51:23 +0100" MODIFIED_BY="Stefan Seidel" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potvin S, Morin M, Cloutier C, Gendron A, Bissonnette A, Marchand S</AU>
<TI>Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2012</YR>
<VL>32</VL>
<PG>684-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Predescu-1973" NAME="Predescu 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Predescu V, Ciurezu T, Timofte G, Roman I</AU>
<TI>Symptomatic relief with flupentixol (Fluanxol) of the anxious-algetic-depressive syndrome complex in neurotic states. A double-blind, placebo-controlled study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1973</YR>
<VL>49</VL>
<PG>15-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rennemo-1982" NAME="Rennemo 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rennemo F, Larsen R, Breivik H</AU>
<TI>Avoiding psychic adverse effects during induction of neurolept anaesthesia with levomepromazine. A double-blind study of levomepromazine and droperidol</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1982</YR>
<VL>26</VL>
<PG>108-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinbrook-1998" NAME="Steinbrook 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinbrook RA, Gosnell JL, Freiberger D</AU>
<TI>Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide</TI>
<SO>Journal of Clinical Anaesthesia</SO>
<YR>1998</YR>
<VL>10</VL>
<PG>494-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Kempen-1992" NAME="Van Kempen 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Kempen GM, Zitman FG, Linssen AC, Edelbroek PM</AU>
<TI>Biochemical measures in patients with a somatoform pain disorder, before, during, and after treatment with amitriptyline with or without flupentixol</TI>
<SO>Biological Psychiatry</SO>
<YR>1992</YR>
<VL>31</VL>
<PG>670-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weaver-2004" NAME="Weaver 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weaver CS, Jones JB, Chisholm CD, Foley MJ, Giles BK, Somerville GG, et al</AU>
<TI>Droperidol versus prochlorperazine for the treatment of acute headache</TI>
<SO>The Journal of Emergency Medicine</SO>
<YR>2004</YR>
<VL>26</VL>
<PG>145-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weber-1980" NAME="Weber 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber H</AU>
<TI>Comparison of the effect of diazepam and levomepromazine on pain in patients with acute lumbago-sciatica</TI>
<SO>Journal of the Oslo City Hospitals</SO>
<YR>1980</YR>
<VL>30</VL>
<PG>65-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wohlzogen-1970" MODIFIED="2008-08-07 17:14:19 +0100" MODIFIED_BY="Jessica Thomas" NAME="Wohlzogen 1970" YEAR="1970">
<REFERENCE MODIFIED="2008-08-07 17:14:19 +0100" MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wohlzogen FX</AU>
<TI>Method, design, and analysis of a comparative study of analgetics</TI>
<SO>Internationale Zeitschrift für klinische Pharmakologie, Therapie und Toxikologie</SO>
<YR>1970</YR>
<VL>4</VL>
<PG>297-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zitman-1992" NAME="Zitman 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zitman FG, Linssen AC, Edelbroek PM, Van Kempen GM</AU>
<TI>Clinical effectiveness of antidepressants and antipsychotics in chronic benign pain</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1992</YR>
<VL>15 Suppl</VL>
<PG>377A-8A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-08-10 10:56:55 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Govorin-1990" MODIFIED="2013-08-10 10:56:55 +0100" MODIFIED_BY="[Empty name]" NAME="Govorin 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-08-10 10:56:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Govorin AV, Neverov IV, Govorin NV</AU>
<TI>Evaluation of the effectiveness of using sulpiride in unstable stenocardia</TI>
<SO>Sovetskaia Meditsina</SO>
<YR>1990</YR>
<VL>10</VL>
<PG>72-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepola-1984" NAME="Lepola 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lepola U, Kokko S, Nuutila J, Gordin A</AU>
<TI>Tiapride and chlordiazepoxide in acute alcohol withdrawal. A controlled clinical trial</TI>
<SO>International Journal of Clinical Pharmacological Research</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>321-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Anna Hobson">
<ADDITIONAL_REFERENCES MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="Stefan Seidel">
<REFERENCE ID="REF-Bloomfield-1964" NAME="Bloomfield 1964" TYPE="JOURNAL_ARTICLE">
<AU>Bloomfield S, Simard-Savoir S, Bernier J, Tetrault L</AU>
<TI>Comparative analgesic activity of levomepromazine and morphine in patients with chronic pain</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1964</YR>
<VL>90</VL>
<PG>1156-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breitbart-1998" MODIFIED="2013-08-10 10:58:02 +0100" MODIFIED_BY="[Empty name]" NAME="Breitbart 1998" TYPE="JOURNAL_ARTICLE">
<AU>Breitbart W</AU>
<TI>Psychotropic adjuvant analgesics for pain in cancer and AIDS</TI>
<SO>Psycho-oncology</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>4</NO>
<PG>333-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burduk-2000" NAME="Burduk 2000" TYPE="JOURNAL_ARTICLE">
<AU>Burduk P, Guzik P, Piechocka M, Bronisz M, Rozek A, Jazdon M, et al</AU>
<TI>Comparison of fentanyl and droperidol mixture (neuroleptanalgesia II) with morphine on clinical outcomes in unstable angina patients</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>3</NO>
<PG>259-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feinberg-2000" NAME="Feinberg 2000" TYPE="JOURNAL_ARTICLE">
<AU>Feinberg SD</AU>
<TI>Prescribing analgesics. How to improve function and avoid toxicity when treating chronic pain</TI>
<SO>Geriatrics</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>11</NO>
<PG>49-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gobel-1997" MODIFIED="2013-08-10 10:59:05 +0100" MODIFIED_BY="[Empty name]" NAME="Gobel 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gobel H, Stadler T</AU>
<TI>Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine</TI>
<SO>Drugs</SO>
<YR>1997</YR>
<VL>53 Suppl 2</VL>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-01-02 13:13:15 +0000" MODIFIED_BY="Stefan Seidel" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jermyn-2001" NAME="Jermyn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jermyn RT</AU>
<TI>A nonsurgical approach to low back pain</TI>
<SO>The Journal of the American Osteopathic Association</SO>
<YR>2001</YR>
<VL>101</VL>
<NO>4 Suppl Pt2</NO>
<PG>S6-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khojainova-2002" MODIFIED="2013-08-10 11:00:45 +0100" MODIFIED_BY="[Empty name]" NAME="Khojainova 2002" TYPE="JOURNAL_ARTICLE">
<AU>Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzalez GR</AU>
<TI>Olanzapine in the management of cancer pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>346-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kiser-2001" MODIFIED="2013-08-10 11:01:10 +0100" MODIFIED_BY="[Empty name]" NAME="Kiser 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kiser RS, Cohen HM, Freedenfeld RN, Jewell C, Fuchs PN</AU>
<TI>Olanzapine for the treatment of fibromyalgia symptoms</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2001</YR>
<VL>22</VL>
<PG>704-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2000" NAME="Lu 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lu SR, Fuh JL, Juang KD, Wang SJ</AU>
<TI>Repetitive intravenous prochlorperazine treatment of patients with refractory chronic daily headache</TI>
<SO>Headache</SO>
<YR>2000</YR>
<VL>40</VL>
<PG>724-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merskey-1997" NAME="Merskey 1997" TYPE="JOURNAL_ARTICLE">
<AU>Merskey H</AU>
<TI>Pharmacological approaches other than opioids in chronic non-cancer pain management</TI>
<SO>Acta Anaesthesiologica Scandinavia</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>187-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montilla-1963" NAME="Montilla 1963" TYPE="JOURNAL_ARTICLE">
<AU>Montilla E, Frederik WS, Cass LJ</AU>
<TI>Analgesic effect of methotrimeprazine and morphine</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1963</YR>
<VL>111</VL>
<PG>725-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nix-1998" MODIFIED="2013-08-23 12:28:07 +0100" MODIFIED_BY="[Empty name]" NAME="Nix 1998" TYPE="JOURNAL_ARTICLE">
<AU>Nix WA</AU>
<TI>What is certain in pain therapy? The analgesic potency of neuroleptics in the treatment of chronic pain. A metaanalysis</TI>
<TO>Was ist gesichert in der Schmerztherapie haben Neuroleptika eine analgetische Potenz?</TO>
<SO>Schmerz</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>30-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paalzow-1992" NAME="Paalzow 1992" TYPE="JOURNAL_ARTICLE">
<AU>Paalzow GH</AU>
<TI>L-dopa induces opposing effects on pain in intact rats: (-)-sulpiride, SCH 23390 or alpha-methyl-DL-p-tyrosine methylester hydrochloride reveals profound hyperalgesia in large antinociceptive doses</TI>
<SO>The Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1992</YR>
<VL>263</VL>
<PG>470-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patt-1994" MODIFIED="2013-08-10 11:12:25 +0100" MODIFIED_BY="[Empty name]" NAME="Patt 1994" TYPE="JOURNAL_ARTICLE">
<AU>Patt RB, Proper G, Reddy S</AU>
<TI>The neuroleptics as adjuvant analgesics</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>7</NO>
<PG>446-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pertovaara-2004" NAME="Pertovaara 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pertovaara A, Martikainen IK, Hagelberg N, Mansikka H, Någren K, Hietala J, et al</AU>
<TI>Striatal dopamine D2/D3 receptor availability correlates with individual response characteristics to pain</TI>
<SO>European Journal of Neuroscience</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>1587-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peschen_x002d_Rosin-2002" MODIFIED="2013-08-10 11:14:22 +0100" MODIFIED_BY="[Empty name]" NAME="Peschen-Rosin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Peschen-Rosin R</AU>
<TI>Chronic facial pain from psychiatric point of view - differential diagnosis and therapeutic strategies</TI>
<TO>Gesichtsschmerzen in der psychiatrie. Differential diagnosen und therapeutische empfehlungen</TO>
<SO>Schmerz</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>395-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-08-21 14:40:32 +0100" MODIFIED_BY="Anna Hobson" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schreiber-1999" NAME="Schreiber 1999" TYPE="JOURNAL_ARTICLE">
<AU>Schreiber S, Getslev V, Backer MM, Weizman R, Pick CG</AU>
<TI>The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency</TI>
<SO>Pharmacology Biochemistry and Behavior</SO>
<YR>1999</YR>
<VL>64</VL>
<NO>1</NO>
<PG>75-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shimizu-2004" NAME="Shimizu 2004" TYPE="JOURNAL_ARTICLE">
<AU>Shimizu T, Iwata S, Morioka H, Masuyama T, Fukuda T, Nomoto M</AU>
<TI>Antinociceptive mechanism of L-DOPA</TI>
<SO>Pain</SO>
<YR>2004</YR>
<VL>110</VL>
<PG>246-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silberstein-2002" MODIFIED="2013-08-10 11:15:40 +0100" MODIFIED_BY="[Empty name]" NAME="Silberstein 2002" TYPE="JOURNAL_ARTICLE">
<AU>Silberstein SD, Peres MFP, Hopkins MM, Shechter AL, Young WB, Rozen TD</AU>
<TI>Olanzapine in the treatment of refractory migraine and chronic daily headache</TI>
<SO>Headache</SO>
<YR>2002</YR>
<VL>42</VL>
<NO>6</NO>
<PG>515-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-12-10 16:41:07 +0000" MODIFIED_BY="Anna Hobson">
<REFERENCE ID="REF-Seidel-2008" MODIFIED="2012-12-10 16:41:07 +0000" MODIFIED_BY="Anna Hobson" NAME="Seidel 2008" TYPE="COCHRANE_REVIEW">
<AU>Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T</AU>
<TI>Antipsychotics for acute and chronic pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-12-10 16:41:07 +0000" MODIFIED_BY="Anna Hobson">
<IDENTIFIER MODIFIED="2012-12-10 16:41:07 +0000" MODIFIED_BY="Anna Hobson" TYPE="DOI" VALUE="10.1002/14651858.CD004844.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-11-18 09:54:37 +0000" MODIFIED_BY="Jessica Thomas">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-11-18 09:54:37 +0000" MODIFIED_BY="Jessica Thomas" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-08-10 10:05:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bussone-1980">
<CHAR_METHODS MODIFIED="2013-08-10 10:01:29 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:05:56 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients, 40 mixed headache, 10 classical migraine<BR/>Age range between 17 and 68 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:01:39 +0100" MODIFIED_BY="[Empty name]">
<P>Random assignment to either 300 mg tiapride or placebo</P>
<P>Duration of treatment: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:01:44 +0100" MODIFIED_BY="[Empty name]">
<P>Headache intensity, frequency and duration reported by headache diary (including 4 weeks pre-intervention)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-10 10:01:53 +0100" MODIFIED_BY="[Empty name]">
<P>Type of pain: chronic headache; 1 dropout due to nausea in the treatment group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:04:36 +0100" MODIFIED_BY="Stefan Seidel" STUDY_ID="STD-Davidsen-1979">
<CHAR_METHODS MODIFIED="2013-08-10 10:02:15 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, controlled, randomised trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:03:39 +0100" MODIFIED_BY="Stefan Seidel">
<P>316 patients, mean age: levomepromazine group 67 years, pethidine group 68 years. Inclusion criteria: acute myocardial infarction within 24 hours prior to admission<BR/>Exclusion criteria: known adverse reactions to narcotics or phenothiazines, treatment with levomepromazine before admission.</P>
<P>Comorbidities: previous hypertension (32 (17% versus 21 (15%)) and previous heart insufficiency (73 (39%) versus 63 (44%)) in the levomepromazine and pethidine groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:03:51 +0100" MODIFIED_BY="[Empty name]">
<P>Patients received one injection upon admission (50 mg pethidine or 12.5 mg levomepromazine) and 100 mg pethidine or 25 mg levomepromazine orally 3 times a day for 3 consecutive days</P>
<P>Further injections were given when needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:04:36 +0100" MODIFIED_BY="Stefan Seidel">
<P>Pain intensity was assessed every 30 minutes during the first 6 hours after admission</P>
<P>90% of patients encountered pain during the course of the acute myocardial infarction</P>
<P>Recurrences of pain in the first 72 hours were observed in 50% of the levomepromazine-treated and in 62% of the pethidine-treated patients (P&lt;0.05)</P>
<P>Incidence of nausea was significantly higher in the pethidine-treated group (P&lt;0.001)</P>
<P>Until a one-year follow-up mortality rates were significantly lower in the levomepromazine-treated group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Type of pain: pain in myocardial infarction; 3 patients died within 30 min after admission, 5 were not treated according to the protocol.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:07:25 +0100" MODIFIED_BY="Stefan Seidel" STUDY_ID="STD-Ginsberg-1983">
<CHAR_METHODS MODIFIED="2013-08-10 10:05:13 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>42 patients, 16 male, 26 female. Inclusion criteria: definite soft tissue rheumatism, sole location of pain, continuous pain, pain of non-specific origin<BR/>Exclusion criteria: not stated</P>
<P>None had received analgesics for the current affection before entering the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:05:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomly assigned to 100 mg tiapride or 200 mg glafenine 3 times daily over a period of 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:07:02 +0100" MODIFIED_BY="Stefan Seidel">
<P>Pain intensity (VAS) was assessed once daily</P>
<P>Initial VAS score: 73 mm (tiapride group) and 73 mm (glafenine group)<BR/>VAS score on day 14: 18.4 mm (tiapride group) and 30.4 mm (glafenine group)</P>
<P>Mild side effects in tiapride group (6 drowsiness, 2 gastric intolerance)</P>
<P>No interruption of treatment<BR/>By the end of treatment, pain had disappeared in 76% of tiapride-treated and 43% of the glafenine-treated patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-10 10:07:25 +0100" MODIFIED_BY="[Empty name]">
<P>Type of pain: acute rheumatic pain; no differences between sexes regarding the efficacy rating of the drugs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:09:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graff_x002d_Radford-2000">
<CHAR_METHODS MODIFIED="2013-08-10 10:07:51 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:08:06 +0100" MODIFIED_BY="[Empty name]">
<P>49 patients, mean age 72.9 years<BR/>Inclusion criteria: post-herpetic neuralgia, pain duration equal or longer to 6 months<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:08:35 +0100" MODIFIED_BY="[Empty name]">
<P>Random assignment to 4 groups:<BR/>Group 1: amitriptyline<BR/>Group 2: amitriptyline + fluphenazine<BR/>Group 3: fluphenazine<BR/>Group 4: placebo (active to mimic anticholinergic side effects)</P>
<P>Starting dose 12.5 mg (amitriptyline) and 1 mg (fluphenazine)<BR/>Maximum dose 200 mg (amitriptyline) and 3 mg (fluphenazine)</P>
<P>8 weeks, one visit per week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:09:08 +0100" MODIFIED_BY="[Empty name]">
<P>Visual analogue scale (VAS), McGill Pain questionnaire (MPQ), side effects scale, Minnesota Multiphasic Personality Inventory (MMPI), Beck Depression Inventory (BDI), Spielberger State Trait Anxiety Inventory (SSTAI)</P>
<P>VAS: significant changes in Group 1 and 2, but none in Group 3 or 4<BR/>Side effects: highest level in Group 3</P>
<P>No evident changes in psychometric measurements</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-10 10:09:39 +0100" MODIFIED_BY="[Empty name]">
<P>Type of pain: post-herpetic neuralgia; 1 dropout due to heavy sedation effect due to amitriptyline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:10:29 +0100" MODIFIED_BY="Jessica Thomas" STUDY_ID="STD-Honkaniemi-2006">
<CHAR_METHODS MODIFIED="2013-08-10 10:10:03 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:10:17 +0100" MODIFIED_BY="[Empty name]">
<P>47 patients, 41 female, 6 male, mean age 36 years, mean duration of headache before admission 75 hours. Inclusion criteria: diagnosis of migraine according to the IHSCC. Exclusion criteria: long QT-interval, usage of drugs prolonging QT-interval, hepatic disease, epilepsy or history of seizures, hyperthyreosis, parkinsonism, chronic psychiatric disease, other neuroleptic medication, and intoxication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:10:22 +0100" MODIFIED_BY="[Empty name]">
<P>Random assignment to either 5 mg haloperidol in 500 ml of normal saline or 500 ml of normal saline alone as a 20 to 30 minute infusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:10:29 +0100" MODIFIED_BY="[Empty name]">
<P>Pain estimation by a VAS between 1 hour and 3 hours after the infusion<BR/>Marked or almost total pain relief</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-07 17:07:10 +0100" MODIFIED_BY="Jessica Thomas">
<P>Type of pain: acute migraine headache; 44 patients included in the placebo-controlled arm of the trial. Of these, 4 were rejected: 2 were included in the study twice, 1 did not fulfil the inclusion criteria and 1 was pain free before the infusion. Of the remaining 40, 36 were female and 4 male. The mean duration of the headache for these 40 patients was 67 h. 80% of patients reported side effects, mainly motor agitation (53%) and sedation (53%).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:12:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnston-1972">
<CHAR_METHODS MODIFIED="2013-08-10 10:11:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:11:45 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients, 32 outpatients, 18 inpatients, 6 men, 44 women, mean age 56 years (age range between 31 to 73 years). Inclusion criteria: terminal cancer with a prognosis of a least a 6 week survival<BR/>Exclusion criteria: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:11:51 +0100" MODIFIED_BY="[Empty name]">
<P>Random assignment to either 25 mg thioridazine p.o. or placebo 3 times a day (final dose 75 mg) for 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:12:13 +0100" MODIFIED_BY="[Empty name]">
<P>Physician's weekly rating of anxiety-tension, insomnia, crying spells, fears, anorexia, and withdrawal, overall rating of emotional complaints and pain</P>
<P>Statistically significant changes in the thioridazine group for anxiety-tension, depressive mood, restlessness, insomnia, crying spells, fears, overall rating of emotional complaints and pain compared to placebo</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-10 10:12:26 +0100" MODIFIED_BY="[Empty name]">
<P>Type of pain: cancer pain; 3 dropouts during follow-up. No untoward effects were observed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:13:19 +0100" MODIFIED_BY="Jessica Thomas" STUDY_ID="STD-Judkins-1982">
<CHAR_METHODS MODIFIED="2013-08-10 10:12:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:12:53 +0100" MODIFIED_BY="[Empty name]">
<P>34 patients, 18 to 70 years, both female and male<BR/>Inclusion criteria: scheduled for elective major upper abdominal surgery, otherwise fit</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:13:04 +0100" MODIFIED_BY="[Empty name]">
<P>Premedication of either 5 mg, 10 mg haloperidol or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:13:19 +0100" MODIFIED_BY="Jessica Thomas">
<P>Analgesic requirement (on-demand system) as measured on a visual analogue scale was assessed every 3 hours within the first 24 hours following surgery</P>
<P>No significant differences between all three conditions regarding the analgesic requirements</P>
<P>Postoperative emesis reduced in the groups receiving haloperidol</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Type of pain: postoperative pain.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:14:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Langemark-1994">
<CHAR_METHODS MODIFIED="2013-08-10 10:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, cross-over, response-conditional pilot study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:13:59 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients, mean age 42 years, recruited by mailed questionnaire<BR/>Inclusion criteria: chronic tension-type headache for at least 6 months and no more than 14 headache-free days per month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:14:05 +0100" MODIFIED_BY="[Empty name]">
<P>Random assignment to either 20 mg paroxetine or 400 mg sulpiride (starting with 200 mg for 1 week) daily for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:14:44 +0100" MODIFIED_BY="[Empty name]">
<P>Headache diary beginning 4 weeks prior to treatment and during 8 weeks of treatment (5-point verbal scale (no/slight/moderate/very troublesome/worst possible headache)</P>
<P>Change in headache score: drug given first, paroxetine (n=18) -0.4, sulpiride (n=19) -0.7</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-10 10:14:49 +0100" MODIFIED_BY="[Empty name]">
<P>Type of pain: chronic tension-type headache; 8 patients dropped out during treatment, 3 headache diaries were incomplete.</P>
<P>1 patient offered paroxetine first never took the drug.</P>
<P>Depression was ruled out using the Bech-Rafaelsen Melancholia rating scale.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:18:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lechin-1989">
<CHAR_METHODS MODIFIED="2013-08-10 10:15:46 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind placebo-controlled cross-over trial<BR/>Four-centre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:16:56 +0100" MODIFIED_BY="[Empty name]">
<P>68 patients joined the study, final number 48 outpatients, 24 men and 24 women, duration of illness 8 to 17 years<BR/>Inclusion criteria: severe facial pain for at least 2 years, clinical diagnosis of trigeminal neuralgia<BR/>Exclusion criteria: placebo responder (improvement of more than 20% during placebo washout period), severe physical illness, history of psychotic episodes, alcohol or drug addiction, epilepsy or any other convulsive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:17:22 +0100" MODIFIED_BY="[Empty name]">
<P>4 weeks of placebo washout, 8 weeks of treatment following random assignment to carbamazepine (final dose of 1200 mg with a 14-day titration period) or pimozide (final dose of 12 mg with a 14-day titration period), 4 weeks with abrupt withdrawal and placebo substitution, 8 weeks of cross-over treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:18:13 +0100" MODIFIED_BY="[Empty name]">
<P>Pain intensity using 6-point registration cards (0 = no pain, 6 = pain present, cannot be ignored, prompt medical advice sought), duration, frequency, basal pain, sensitivity of trigger zones, number of relief tablets</P>
<P>Total trigeminal neuralgia score reduction of 78.1 % (pimozide group) compared to 49.7% (carbamazepine group), statistically significant (P&lt;0.001) at week 10</P>
<P>Adverse effects (hand tremors, involuntary movements during sleep, slight Parkinson's symptoms) observed in 40 of 48 patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Type of pain: trigeminal neuralgia; 9 patients were not admitted to the treatment phase, 6 patients were excluded.</P>
<P>11 were not included in the statistical analysis.</P>
<P>All patients refused interruption of pimozide treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-18 09:51:35 +0000" MODIFIED_BY="Stefan Seidel" STUDY_ID="STD-Richman-2002">
<CHAR_METHODS MODIFIED="2013-11-18 09:44:53 +0000" MODIFIED_BY="Stefan Seidel">
<P>Double-blind single-center randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-18 09:50:04 +0000" MODIFIED_BY="Stefan Seidel">
<P>Twenty-nine patients admitted to emergency department due to acute headaches</P>
<P>Inclusion criteria: migraine with or without aura according the criteria of the International Headache Society<BR/>Exclusion criteria: refusal to give informed consent, known allergy to butyrophenones and/or narcotics, ingestion of antiemetic, antihistamine, phenothiazine, and/or narcotic medication within 24 hours of ED presentation, diagnostic work-up because headache was not typical in character compared with the patient's prior migraine pattern</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-18 09:50:37 +0000" MODIFIED_BY="Stefan Seidel">
<P>2.5mg intramuscular droperidol (group 1) and 1.5mg/kg intramuscluar meperidine </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-18 09:51:10 +0000" MODIFIED_BY="Stefan Seidel">
<P>pain intensity (VAS) after 30 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-18 09:51:35 +0000" MODIFIED_BY="Stefan Seidel">
<P>none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:19:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roux-1983">
<CHAR_METHODS MODIFIED="2013-08-10 10:18:44 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:19:02 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients<BR/>Headache following rachiocentesis (observation period 48 hours)<BR/>Inclusion criteria: not stated<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Random assignment to either 200 mg tiapride i.v. or placebo i.v. after rachiocentesis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:19:40 +0100" MODIFIED_BY="[Empty name]">
<P>Occurrence of headache</P>
<P>No headache in 86.7% of patients receiving tiapride and in 46.6% of patients receiving placebo</P>
<P>Statistically significant difference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Type of pain: post-rachiocentesis headache.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-10 10:26:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zitman-1991">
<CHAR_METHODS MODIFIED="2013-08-10 10:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled cross-over trial study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-10 10:24:59 +0100" MODIFIED_BY="[Empty name]">
<P>34 patients, mean age 34 years<BR/>Inclusion criteria: pain duration at least 6 months, age between 30 and 60 years<BR/>Exclusion criteria: severe psychiatric disease, renal, hepatic or cardiac disorders, epilepsy, glaucoma, hypertension, prostate dysfunction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-10 10:25:11 +0100" MODIFIED_BY="[Empty name]">
<P>Baseline (2 weeks) 75 mg amitriptyline and 3 mg flupentixol; first treatment (5 weeks) 75 mg amitriptyline and 3 mg flupentixol (scheme A) or 75 mg amitriptyline alone (scheme B); washout period (2 weeks) both groups placebo; 2nd treatment (5 weeks) crossing-over from scheme A to B and vice versa</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-10 10:26:15 +0100" MODIFIED_BY="[Empty name]">
<P>Zung depression scale, Hamilton depression scale, clinical screening for extrapyramidal side effects, Abnormal Involuntary Movement Scale (AIMS), pain intensities (numeric scale 0 = no pain, 10 = unbearable pain)</P>
<P>No differences between the amitriptyline group and the amitriptyline + flupentixol group concerning the pain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Type of pain: somatoform pain disorder; 2 refused to participate, 9 dropped out during treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>i.v. - intravenous</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adeloye-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>no data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anon-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>not able to identify authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barbier-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>haloperidol in combination with buzepide metiodide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-18 09:23:41 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Brousseau-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-18 09:23:41 +0000" MODIFIED_BY="Anna Hobson">
<P>pediatric population studied</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 10:35:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cerbo-1982a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 10:35:18 +0100" MODIFIED_BY="[Empty name]">
<P>cross-over trial, no data on first session given separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 10:35:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cerbo-1982b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 10:35:31 +0100" MODIFIED_BY="[Empty name]">
<P>cross-over trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 10:35:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clavel-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 10:35:39 +0100" MODIFIED_BY="[Empty name]">
<P>cross-over trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 10:35:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clavel-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 10:35:46 +0100" MODIFIED_BY="[Empty name]">
<P>cross-over trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-21 15:05:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corazza-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-21 15:05:48 +0100" MODIFIED_BY="[Empty name]">
<P>mixed outcome<BR/>no distinct outcome pain parameter, overall score</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-07 13:23:05 +0000" MODIFIED_BY="Stefan Seidel" STUDY_ID="STD-Friedman-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-07 13:23:05 +0000" MODIFIED_BY="Stefan Seidel">
<P>control group: metoclopramide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 10:39:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Girard-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 10:39:14 +0100" MODIFIED_BY="[Empty name]">
<P>open-label study, no control condition, no randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gomez_x002d_Perez-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>fluphenazine in combination with nortriptyline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gomez_x002d_Perez-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>cross-over design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grillage-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>control group: diazepam</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hakkarainen-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>cross-over</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hakkarainen-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>no randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-02 13:59:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hill-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-02 13:59:49 +0000" MODIFIED_BY="[Empty name]">
<P>control group: droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jokinen-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>control group: diazepam<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-02 14:02:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kostic-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-02 14:02:49 +0000" MODIFIED_BY="[Empty name]">
<P>combination</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lam-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>pain no outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lancaster_x002d_Smith-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>combination</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 10:39:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Derff-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 10:39:38 +0100" MODIFIED_BY="[Empty name]">
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lobera-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>mix outcome (pain/nausea/emesis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-07 13:22:37 +0000" MODIFIED_BY="Stefan Seidel" STUDY_ID="STD-Macarri-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-07 13:22:37 +0000" MODIFIED_BY="Stefan Seidel">
<P>control group: antipsychotic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maina-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>single blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>fluphenazine in combination with nortriptyline<BR/>no pain outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Menault-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>no randomization, no placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mendel-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>combination of amitriptyline and fluphenazine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mereto-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>in all three groups perphenazine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-07 13:23:16 +0000" MODIFIED_BY="Stefan Seidel" STUDY_ID="STD-Miller-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-07 13:23:16 +0000" MODIFIED_BY="Stefan Seidel">
<P>control group: octreotide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pagliarini-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>single blind<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pisani-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>no blinding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-07 13:11:17 +0000" MODIFIED_BY="Stefan Seidel" STUDY_ID="STD-Potvin-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-07 13:11:17 +0000" MODIFIED_BY="Stefan Seidel">
<P>pain no primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Predescu-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>no pain outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-07 13:11:14 +0000" MODIFIED_BY="Stefan Seidel" STUDY_ID="STD-Rennemo-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-07 13:11:14 +0000" MODIFIED_BY="Stefan Seidel">
<P>pain no primary outcome<BR/>not compared to placebo or other compound in respect to pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 10:40:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinbrook-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 10:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>postoperative pain was treated as needed with fentanyl or morphine<BR/>no pain outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Kempen-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>pain no outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-18 09:24:04 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Weaver-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-18 09:24:04 +0000" MODIFIED_BY="Anna Hobson">
<P>comparison of two antipsychotics without placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weber-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>additional pain medication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wohlzogen-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>healthy subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zitman-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>no randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Govorin-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lepola-1984">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-11-18 09:54:37 +0000" MODIFIED_BY="Stefan Seidel">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-11-18 09:54:13 +0000" MODIFIED_BY="Stefan Seidel" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:25:30 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Bussone-1980">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:39:59 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Davidsen-1979">
<DESCRIPTION>
<P>Not reported - stated to be "on admission the patient was allocated the first available box"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:39:52 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Ginsberg-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-10 12:24:14 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Graff_x002d_Radford-2000">
<DESCRIPTION>
<P>Not described - states &#8220;randomly assigned&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:42:42 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Honkaniemi-2006">
<DESCRIPTION>
<P>Described as "...patients were randomized by envelope selection."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:49:18 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Johnston-1972">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:57:42 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Judkins-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:59:15 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Langemark-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:04:02 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Lechin-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-18 09:54:13 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Richman-2002">
<DESCRIPTION>
<P>only patients with acute migraine, presumably those with higher pain intensity due to presentation in ED</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:05:40 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Roux-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:07:00 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Zitman-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-11-18 09:54:18 +0000" MODIFIED_BY="Stefan Seidel" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:25:42 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Bussone-1980">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:46:19 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Davidsen-1979">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:39:49 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Ginsberg-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:38:34 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Graff_x002d_Radford-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:46:53 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Honkaniemi-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:49:29 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Johnston-1972">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:57:48 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Judkins-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:59:41 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Langemark-1994">
<DESCRIPTION>
<P>Not reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:03:19 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Lechin-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-18 09:54:18 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Richman-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:05:21 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Roux-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:07:06 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Zitman-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-11-18 09:54:25 +0000" MODIFIED_BY="Stefan Seidel" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 14:25:49 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Bussone-1980">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 14:46:21 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Davidsen-1979">
<DESCRIPTION>
<P>Described as "tablets and vials of identical appearance were dispensed ..." and "...the sealed code was kept in the pharmacy ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 14:39:46 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Ginsberg-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-10 12:24:42 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Graff_x002d_Radford-2000">
<DESCRIPTION>
<P>Double-dummy method. &#8220;Active&#8221; placebo (glycopyrrolate) to mimic anticholinergic side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 14:46:54 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Honkaniemi-2006">
<DESCRIPTION>
<P>Described as "...treatment was carried out by an attending nurse, who prepared and blinded the infusion."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 14:50:03 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Johnston-1972">
<DESCRIPTION>
<P>Described as "matching placebo capsules"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 14:58:00 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Judkins-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 15:04:18 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Langemark-1994">
<DESCRIPTION>
<P>Double-dummy technique described as "identically looking placebo tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 15:04:38 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Lechin-1989">
<DESCRIPTION>
<P>Described as "identical dark capsules"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-18 09:54:25 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Richman-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 15:05:44 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Roux-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-26 15:07:23 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Zitman-1991">
<DESCRIPTION>
<P>Described as "identical placebo tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-11-18 09:54:29 +0000" MODIFIED_BY="Stefan Seidel" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 14:26:01 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Bussone-1980">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 14:46:22 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Davidsen-1979">
<DESCRIPTION>
<P>Described as "tablets and vials of identical appearance were dispensed ..." and "...the sealed code was kept in the pharmacy ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 14:39:43 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Ginsberg-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-10 12:24:59 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Graff_x002d_Radford-2000">
<DESCRIPTION>
<P>Double-dummy method. &#8220;Active&#8221; placebo (glycopyrrolate) to mimic anticholinergic side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 14:46:56 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Honkaniemi-2006">
<DESCRIPTION>
<P>Described as "...treatment was carried out by an attending nurse, who prepared and blinded the infusion."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 14:50:08 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Johnston-1972">
<DESCRIPTION>
<P>Described as "matching placebo capsules"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 14:58:05 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Judkins-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 15:04:19 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Langemark-1994">
<DESCRIPTION>
<P>Double-dummy technique described as "identically looking placebo tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 15:04:41 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Lechin-1989">
<DESCRIPTION>
<P>Described as "identical dark capsules"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-18 09:54:29 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Richman-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 15:05:52 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Roux-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-26 15:07:27 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Zitman-1991">
<DESCRIPTION>
<P>Described as "identical placebo tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-11-18 09:54:37 +0000" MODIFIED_BY="Stefan Seidel" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:17:49 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Bussone-1980">
<DESCRIPTION>
<P>All participants were included in the analysis, no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:16:48 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Davidsen-1979">
<DESCRIPTION>
<P>All participants were included in the analysis, no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:16:03 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Ginsberg-1983">
<DESCRIPTION>
<P>All participants were included in the analysis, no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-10 12:25:12 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Graff_x002d_Radford-2000">
<DESCRIPTION>
<P>Imputation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:09:28 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Honkaniemi-2006">
<DESCRIPTION>
<P>Imputation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:13:21 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Johnston-1972">
<DESCRIPTION>
<P>Imputation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:15:06 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Judkins-1982">
<DESCRIPTION>
<P>All participants were included in the analysis, no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:01:32 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Langemark-1994">
<DESCRIPTION>
<P>Imputation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:05:01 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Lechin-1989">
<DESCRIPTION>
<P>Imputation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-18 09:54:37 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Richman-2002">
<DESCRIPTION>
<P>Imputation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:05:23 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Roux-1983">
<DESCRIPTION>
<P>Imputation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-26 15:07:44 +0000" MODIFIED_BY="Stefan Seidel" RESULT="UNKNOWN" STUDY_ID="STD-Zitman-1991">
<DESCRIPTION>
<P>Imputation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2013-11-18 09:53:31 +0000" MODIFIED_BY="Stefan Seidel" NO="9">
<NAME>Size</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:52:46 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Bussone-1980">
<DESCRIPTION>
<P>Fewer than 50 participants/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:52:32 +0000" MODIFIED_BY="Stefan Seidel" RESULT="YES" STUDY_ID="STD-Davidsen-1979">
<DESCRIPTION>
<P>&gt;100 participants/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:08:20 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Ginsberg-1983">
<DESCRIPTION>
<P>Fewer than 50 participants/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-10 12:25:22 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Graff_x002d_Radford-2000">
<DESCRIPTION>
<P>Fewer than 50 participants/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:52:59 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Honkaniemi-2006">
<DESCRIPTION>
<P>Fewer than 50 participants/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:56:44 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Johnston-1972">
<DESCRIPTION>
<P>Fewer than 50 patients/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 14:56:57 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Judkins-1982">
<DESCRIPTION>
<P>Fewer than 50 patients/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:08:34 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Langemark-1994">
<DESCRIPTION>
<P>Fewer than 50 patients/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:03:08 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Lechin-1989">
<DESCRIPTION>
<P>Fewer than 50 patients/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-18 09:53:31 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Richman-2002">
<DESCRIPTION>
<P>Very small group size</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:05:36 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Roux-1983">
<DESCRIPTION>
<P>Fewer than 50 patients/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 15:06:06 +0000" MODIFIED_BY="Stefan Seidel" RESULT="NO" STUDY_ID="STD-Zitman-1991">
<DESCRIPTION>
<P>Fewer than 50 patients/treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2013-11-18 09:29:54 +0000" MODIFIED_BY="Jessica Thomas">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-11-18 09:29:54 +0000" MODIFIED_BY="Anna Hobson" NO="1">
<TITLE>Side effects</TITLE>
<TABLE COLS="4" ROWS="13">
<TR>
<TH>
<P>Author/Year</P>
</TH>
<TH>
<P>Substance</P>
</TH>
<TH>
<P>Type of side effect</P>
</TH>
<TH>
<P>Percentage</P>
</TH>
</TR>
<TR>
<TD>
<P>Ginsberg 1983</P>
</TD>
<TD>
<P>Tiapride</P>
</TD>
<TD>
<P>Drowsiness (moderate to mild), mild gastric intolerance</P>
</TD>
<TD>
<P>38.1%</P>
</TD>
</TR>
<TR>
<TD>
<P>Lechin 1989</P>
</TD>
<TD>
<P>Pimozide</P>
</TD>
<TD>
<P>Physical and mental retardation, hand tremors, memory impairment, involuntary movements during sleep (jerkings) and slight Parkinson's disease manifestations</P>
</TD>
<TD>
<P>83.3%</P>
</TD>
</TR>
<TR>
<TD>
<P>Langemark 1994</P>
</TD>
<TD>
<P>Sulpiride</P>
</TD>
<TD>
<P>Sedation, depression, nausea, sleep disturbance, increased dreaming, uneasiness, weight gain, obstipation, amenorrhoea, galactorrhoea, impotence, restless legs, micturation difficulties, polyuria, accomodation difficulties, dry mouth, orthostatic hypotension</P>
</TD>
<TD>
<P>author only provided incidences, at least 34%</P>
</TD>
</TR>
<TR>
<TD>
<P>Roux 1983</P>
</TD>
<TD>
<P>Tiapride</P>
</TD>
<TD>
<P>no side effects reported</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>Johnston 1972</P>
</TD>
<TD>
<P>Thioridazine</P>
</TD>
<TD>
<P>No untoward effects were observed or reported at any time during the study</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>Davidsen 1979</P>
</TD>
<TD>
<P>Levomepromazine</P>
</TD>
<TD>
<P>Dry mouth</P>
</TD>
<TD>
<P>59%</P>
</TD>
</TR>
<TR>
<TD>
<P>Graff-Radford 2000</P>
</TD>
<TD>
<P>Fluphenazine</P>
</TD>
<TD>
<P>Sleepiness, dry mouth</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>Zitman 1991</P>
</TD>
<TD>
<P>Flupentixol</P>
</TD>
<TD>
<P>Dry mouth</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>Judkins 1982</P>
</TD>
<TD>
<P>Haloperidol</P>
</TD>
<TD>
<P>No serious side effects were observed, dry mouth</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>Bussone 1980</P>
</TD>
<TD>
<P>Tiapride</P>
</TD>
<TD>
<P>No extrapyramidal, neuroendocrine or neurovegetative side effects were observed</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>Honkaniemi 2006</P>
</TD>
<TD>
<P>Haloperidol</P>
</TD>
<TD>
<P>Motor agitation, sedation, hyperventilation and shortness of breath</P>
</TD>
<TD>
<P>80%</P>
</TD>
</TR>
<TR>
<TD>
<P>Richman 2002</P>
</TD>
<TD>
<P>Droperidol</P>
</TD>
<TD>
<P>Sedation, akathisia</P>
</TD>
<TD>
<P>Sedation: 6.7% (droperidol) vs. 13.4% (meperidine); akathisia 13.3% (only droperidol reported)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-08-10 11:16:08 +0100" MODIFIED_BY="Anna Hobson">
<COMPARISON ID="CMP-001" MODIFIED="2013-08-10 11:16:08 +0100" MODIFIED_BY="Anna Hobson" NO="1">
<NAME>Reduction in pain intensity</NAME>
<CONT_OUTCOME CHI2="19.977663002769795" CI_END="-1.3211060984608651" CI_START="-2.9973889730867778" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1592475357738214" ESTIMABLE="YES" I2="84.98322852085319" I2_Q="94.63899992422273" ID="CMP-001.01" MODIFIED="2012-12-10 16:32:44 +0000" MODIFIED_BY="Anna Hobson" NO="1" P_CHI2="1.7156245700367112E-4" P_Q="1.5678291493292917E-5" P_Z="4.433769553797057E-7" Q="18.653236072842525" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="5.049323676671214">
<NAME>Acute and chronic pain continuous data - difference posttreatment minus baseline</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.159772286088384" CI_START="-5.8802277139116175" DF="0" EFFECT_SIZE="-4.5200000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="7.370993046958622E-11" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="37.967446247108434" Z="6.512907448889606">
<NAME>acute</NAME>
<CONT_DATA CI_END="-3.159772286088384" CI_START="-5.8802277139116175" EFFECT_SIZE="-4.5200000000000005" ESTIMABLE="YES" MEAN_1="-5.45" MEAN_2="-0.93" ORDER="11859" SD_1="2.77" SD_2="1.4" SE="0.694006484119565" STUDY_ID="STD-Honkaniemi-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="37.967446247108434"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3244269299272726" CI_END="0.34982841124502284" CI_START="-1.778494292613368" DF="2" EFFECT_SIZE="-0.7143329406841726" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.5157086046305428" P_Z="0.18829061120982787" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="54" WEIGHT="62.03255375289157" Z="1.3156527759379852">
<NAME>chronic</NAME>
<CONT_DATA CI_END="1.372941791756893" CI_START="-2.5929417917568927" EFFECT_SIZE="-0.6099999999999999" ESTIMABLE="YES" MEAN_1="-1.15" MEAN_2="-0.54" ORDER="11860" SD_1="2.79" SD_2="2.35" SE="1.0117235864526515" STUDY_ID="STD-Graff_x002d_Radford-2000" TOTAL_1="13" TOTAL_2="13" WEIGHT="17.865480169235642"/>
<CONT_DATA CI_END="0.9632623326252308" CI_START="-6.703262332625231" EFFECT_SIZE="-2.87" ESTIMABLE="YES" MEAN_1="-7.84" MEAN_2="-4.97" ORDER="11861" SD_1="1.52" SD_2="9.46" SE="1.9557820260277816" STUDY_ID="STD-Lechin-1989" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.780766601430523"/>
<CONT_DATA CI_END="0.8355024274151249" CI_START="-1.8355024274151246" EFFECT_SIZE="-0.4999999999999999" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-0.9" ORDER="11862" SD_1="2.43" SD_2="1.41" SE="0.6813913102227375" STUDY_ID="STD-Zitman-1991" TOTAL_1="17" TOTAL_2="17" WEIGHT="39.386306982225406"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.039441832909654" CI_END="0.7300719435264361" CI_START="0.25158269813871326" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" I2="75.2441044737191" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.13663434106171368" LOG_CI_START="-0.5993192295274752" LOG_EFFECT_SIZE="-0.36797678529459443" METHOD="MH" NO="2" P_CHI2="0.044448608778342336" P_Q="1.0" P_Z="0.001823620555557872" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="3.117548311187619">
<NAME>Acute pain dichotomous data</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.039441832909654" CI_END="0.7300719435264361" CI_START="0.25158269813871326" DF="1" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" I2="75.2441044737191" ID="CMP-001.02.01" LOG_CI_END="-0.13663434106171368" LOG_CI_START="-0.5993192295274752" LOG_EFFECT_SIZE="-0.36797678529459443" NO="1" P_CHI2="0.044448608778342336" P_Z="0.001823620555557872" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="3.117548311187619">
<NAME>acute</NAME>
<DICH_DATA CI_END="1.4367638899864845" CI_START="0.3681367714772441" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.15738540438957016" LOG_CI_START="-0.4339908007221331" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="11863" O_E="0.0" SE="0.34737731024204166" STUDY_ID="STD-Ginsberg-1983" TOTAL_1="21" TOTAL_2="21" VAR="0.12067099567099568" WEIGHT="39.285714285714285"/>
<DICH_DATA CI_END="0.5762175133040954" CI_START="0.09608059547140196" EFFECT_SIZE="0.23529411764705882" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" LOG_CI_END="-0.23941354609770635" LOG_CI_START="-1.0173643140029167" LOG_EFFECT_SIZE="-0.6283889300503115" ORDER="11864" O_E="0.0" SE="0.4569721319859284" STUDY_ID="STD-Honkaniemi-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.20882352941176474" WEIGHT="60.714285714285715"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2013-06-01 13:14:08 +0100" MODIFIED_BY="Anna Hobson" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="74" TOTAL_2="74" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Acute and chronic pain continuous data - mean after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>acute</NAME>
<CONT_DATA CI_END="-2.494265083641068" CI_START="-5.605734916358932" EFFECT_SIZE="-4.05" ESTIMABLE="YES" MEAN_1="2.25" MEAN_2="6.3" ORDER="11865" SD_1="2.53" SD_2="2.49" SE="0.7937568897338781" STUDY_ID="STD-Honkaniemi-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>chronic</NAME>
<CONT_DATA CI_END="2.5687502629799943" CI_START="-1.4887502629799942" EFFECT_SIZE="0.54" ESTIMABLE="YES" MEAN_1="5.39" MEAN_2="4.85" ORDER="11866" SD_1="2.78" SD_2="2.49" SE="1.0350956849118236" STUDY_ID="STD-Graff_x002d_Radford-2000" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.14237575494480215" CI_START="-8.077624245055198" EFFECT_SIZE="-4.109999999999999" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="5.1" ORDER="11867" SD_1="1.52" SD_2="9.8" SE="2.0243352818476823" STUDY_ID="STD-Lechin-1989" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.9032237555440106" CI_START="-2.1032237555440108" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.6" ORDER="11868" SD_1="1.8" SD_2="2.6" SE="0.7669649888473705" STUDY_ID="STD-Zitman-1991" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-11-18 09:54:38 +0000" MODIFIED_BY="Stefan Seidel">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-11-18 09:54:38 +0000" MODIFIED_BY="Stefan Seidel" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATYAAAK9CAIAAAAhQdd4AAAgcklEQVR42u3dv44cx9nF4QEMGA42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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-03-24 15:40:03 +0000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-03-24 15:40:03 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-11-07 20:24:35 +0000" MODIFIED_BY="Stefan Seidel">Studies on prochlorperazine and droperidol</TITLE>
<DATE_SUBMITTED>
<DATE DAY="31" MONTH="10" YEAR="2013"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-11-07 20:25:45 +0000" MODIFIED_BY="Stefan Seidel">
<P>
<I>Feedback: The methods state that the update included two additional antipsychotics - prochlorperazine and droperidol that were excluded from the original review. This is in contrast with the results text where you state: </I>
</P>
<P>
<I>Three high-quality studies (Brousseau 2004; Richman 2002; Weaver 2004) were excluded because the antipsychotics tested (prochlorperazine and droperidol) had not been within the scope of antipsychotics of our protocol and because they were not within the scope of our search strategy.</I>
</P>
<P>
<I>It is unclear why these studies were not included in the update (even if left out of the original) if part of the purpose was to expand it to include these other drugs. Ultimately, two of the most commonly used antipsychotics in the US (including frequent use for acutely painful conditions) are left out of the review making much less clinically useful to practitioners.</I>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-11-18 09:44:03 +0000" MODIFIED_BY="Stefan Seidel">
<P>We are grateful for this clinically relevant feedback and revised our review accordingly. To summarize, the reasons for exclusion of the studies have been corrected (see <LINK REF="STD-Brousseau-2004" TYPE="STUDY">Brousseau 2004</LINK> and <LINK REF="STD-Weaver-2004" TYPE="STUDY">Weaver 2004</LINK>). Another study (Richman 2002a) investigating the effect of droperidol on migraine headaches has now been included.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2015-03-24 15:40:03 +0000" MODIFIED_BY="[Empty name]">
<P>Authors and editors.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-09-04 14:25:44 +0100" MODIFIED_BY="Jessica Thomas">
<APPENDIX ID="APP-01" MODIFIED="2013-01-02 13:13:15 +0000" MODIFIED_BY="Jessica Thomas" NO="1">
<TITLE MODIFIED="2008-08-07 16:33:22 +0100" MODIFIED_BY="Jessica Thomas">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-02 13:13:15 +0000" MODIFIED_BY="Jessica Thomas">
<P>
<I>A , B, C combined with AND</I>
</P>
<P>A. Neuroleptic/antipsychotic drugs (combined with OR)<BR/>Free Term<BR/>neurolept*, antipsychotic*, Amisulpride*, Chormethiazole*, Clomethiazole*, Distraneurin*, Chlorpromazin*, Aminazine*, Chlorazine*, Chlordelazine*, Contomin*, Fenactil*, Largactil*, Propaphenin*, Thorazine*, Flupenthixol decanoate*, Emergil*, Fluanxol*, Flupentixol*, alphaFlupenthixol*, cisFlupenthixol*, Fluphenazin*, Fluphenazine decanoate*, Flufenazin*, Fluphenazine Hydrochloride*, Lyogen*, Prolixin*, Haloperidol*, Haldol*, Levomepromazin*, Levomeprazin*, Levopromazine*, Tisercin*, Tizercine*, Tizertsin*, Methotrimeprazine*, Loxapine*, Loxapinsuccinate*, Oxilapine*, Cloxazepine*, Loxapine Monohydrochloride*, Loxipine Maleate*, Loxipine Succinate*, Loxitane*, Asendin*, Desmethylloxapine*, Amoxapine*, Olanzapine*, Perphenazine*, Chlorpiprazine*, Perfenazine*, Trilafonor*, Pimozide*, Prothipendyl*, Quetiapine*, Fumarate*, Risperidone*, Risperidal*, Sulpiride*, Dogmatil*, Eglonyl*, Sulperide*, Thioridazine*, Meleril*, Mellaril*, Melleril*, Melleryl*, Sonapax*, Thioridazine Hydrochloride*, Tiaprid*, Tiapridal*, Trifluoperazine Hydrochloride*, Trifluoroperazine*, Triftazin*, Stelazine*, Trifluperazine*, Tripfluoperazine Hydrochloride*, Cisordinol*, Zuclopenthixol*, Clopenthixol*, Clozapine*, Melperone hydrochloride*, Ziprasidone*, Zotemine*<BR/>MeSH<BR/>Pimozide, Perphenazine, explode Loxapine, Methotrimeprazine, Haloperidol, Fluphenazine, Flupenthixol, Chlorpromazine, Chlormethiazole, Antipsychotic-Agents, Clopenthixol, Trifluoperazine, Tiapride, Thioridazine, Sulpiride, Risperidone, Fumarates</P>
<P>B. Pain (combined with OR)<BR/>Free Term<BR/>pain*<BR/>MeSH<BR/>explode Pain</P>
<P>C. RCT-Filter<BR/>See Cochrane Handbook of Systematic Review of Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-08-10 11:18:10 +0100" MODIFIED_BY="Jessica Thomas" NO="2">
<TITLE MODIFIED="2008-08-07 16:34:22 +0100" MODIFIED_BY="Jessica Thomas">Additional search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-08-10 11:18:10 +0100" MODIFIED_BY="Jessica Thomas">
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Database searched</P>
</TH>
<TH>
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<P>
<I>A , B, C combined with AND</I>
<BR/>
<BR/>A. Neuroleptic/antipsychotic drugs (combined with OR)<BR/>Free Term<BR/>neurolept*, antipsychotic*<BR/>EMTREE<BR/>Neuroleptanalgesia<BR/>explode neuroleptic-agent<BR/>
<BR/>B.Pain (combined with OR)<BR/>Free Term<BR/>pain*<BR/>EMTREE<BR/>explode Pain<BR/>
<BR/>C.RCT-Filter (combined with OR)<BR/>Free Term<BR/>random* in ab,ti<BR/>cross?over* in ab,ti<BR/>factorial* in ab,ti<BR/>placebo* in ab,ti<BR/>volunteer* in ab,ti<BR/>(singl* or doubl* or trebl* or tripl*) near (blind* or mask*) in ab,ti<BR/>EMTREE<BR/>randomized-controlled-trial, randomization, controlled-study, multicenter-study, phase-3-clinical-trial, phase-4-clinical-trial, double-blind-procedure, single-blind-procedure<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>PSYNDEX</P>
</TD>
<TD>
<P>
<I>A , B, C combined with AND</I>
<BR/>
<BR/>A. Neuroleptic/antipsychotic drugs (combined with OR)<BR/>Free Term<BR/>neurolept*, antipsychoti*, Amisulpride*, Chormethiazole*, Clomethiazole*, Distraneurin*, Chlorpromazin*, Aminazine*, Chlorazine*, Chlordelazine*, Contomin*, Fenactil*, Largactil*, Propaphenin*, Thorazine*, Flupenthixol decanoate*, Emergil*, Fluanxol*, Flupentixol*, alphaFlupenthixol*, cisFlupenthixol*, Fluphenazin*, Fluphenazine decanoate*, Flufenazin*, Fluphenazine Hydrochloride*, Lyogen*, Prolixin*, Haloperidol*, Haldol*, Levomepromazin*, Levomeprazin*, Levopromazine*, Tisercin*, Tizercine*, Tizertsin*, Methotrimeprazine*, Loxapine*, Loxapinsuccinate*, Oxilapine*, Cloxazepine*, Loxapine Monohydrochloride*, Loxipine Maleate*, Loxipine Succinate*, Loxitane*, Asendin*, Desmethylloxapine*, Amoxapine*, Olanzapine*, Perphenazine*, Chlorpiprazine*, Perfenazine*, Trilafonor*, Pimozide*, Prothipendyl*, Quetiapine*, Fumarate*, Risperidone*, Risperidal*, Sulpiride*, Dogmatil*, Eglonyl*, Sulperide*, Thioridazine*, Meleril*, Mellaril*, Melleril*, Melleryl*, Sonapax*, Thioridazine Hydrochloride*, Tiaprid*, Tiapridal*, Trifluoperazine Hydrochloride*, Trifluoroperazine*, Triftazin*, Stelazine*, Trifluperazine*, Tripfluoperazine Hydrochloride*, Cisordinol*, Zuclopenthixol*, Clopenthixol*<BR/>Thesaurus<BR/>Explode Neuroleptic-Drugs<BR/>
<BR/>B. Pain (combined with OR)<BR/>Free Term<BR/>pain*<BR/>schmerz*<BR/>Thesaurus<BR/>explode Pain<BR/>
<BR/>C. RCT-Filter (combined with OR)<BR/>placebo*<BR/>random*<BR/>control*<BR/>kontroll*<BR/>prospectiv*<BR/>prospekti*<BR/>volunteer*<BR/>(clin* near trial*)<BR/>(klin* near fall*)<BR/>(compar* near stud*)<BR/>(vergleich* near stud*)<BR/>(singl* or doubl* or trebl* or tripl*) near (blind* or mask*)</P>
</TD>
</TR>
<TR>
<TD>
<P>PsycINFO</P>
</TD>
<TD>
<P>
<I>A , B, C combined with AND</I>
<BR/>
<BR/>A. Neuroleptic/antipsychotic drugs (combined with OR)<BR/>Free Term<BR/>neurolept*, antipsychotic*, Amisulpride*, Chormethiazole*, Clomethiazole*, Distraneurin*, Chlorpromazin*, Aminazine*, Chlorazine*, Chlordelazine*, Contomin*, Fenactil*, Largactil*, Propaphenin*, Thorazine*, Flupenthixol decanoate*, Emergil*, Fluanxol*, Flupentixol*, alphaFlupenthixol*, cisFlupenthixol*, Fluphenazin*, Fluphenazine decanoate*, Flufenazin*, Fluphenazine Hydrochloride*, Lyogen*, Prolixin*, Haloperidol*, Haldol*, Levomepromazin*, Levomeprazin*, Levopromazine*, Tisercin*, Tizercine*, Tizertsin*, Methotrimeprazine*, Loxapine*, Loxapinsuccinate*, Oxilapine*, Cloxazepine*, Loxapine Monohydrochloride*, Loxipine Maleate*, Loxipine Succinate*, Loxitane*, Asendin*, Desmethylloxapine*, Amoxapine*, Olanzapine*, Perphenazine*, Chlorpiprazine*, Perfenazine*, Trilafonor*, Pimozide*, Prothipendyl*, Quetiapine*, Fumarate*, Risperidone*, Risperidal*, Sulpiride*, Dogmatil*, Eglonyl*, Sulperide*, Thioridazine*, Meleril*, Mellaril*, Melleril*, Melleryl*, Sonapax*, Thioridazine Hydrochloride*, Tiaprid*, Tiapridal*, Trifluoperazine Hydrochloride*, Trifluoroperazine*, Triftazin*, Stelazine*, Trifluperazine*, Tripfluoperazine Hydrochloride*, Cisordinol*, Zuclopenthixol*, Clopenthixol*<BR/>Thesaurus<BR/>Explode Neuroleptic-Drugs<BR/>
<BR/>B.Pain (combined with OR)<BR/>Free Term<BR/>pain*<BR/>Thesaurus<BR/>explode Pain<BR/>
<BR/>C.RCT-Filter (combined with OR)<BR/>placebo*<BR/>random*<BR/>control*<BR/>prospectiv*<BR/>volunteer*<BR/>(clin* near trial*)<BR/>(compar* near stud*)<BR/>(singl* or doubl* or trebl* or tripl*) near (blind* or mask*)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>The Cochrane LIbrary</I>
</P>
</TD>
<TD>
<P>(Controlled vocabulary terms (MeSH) are presented in uppercase text; freetext terms in lowercase text.)<BR/>
<BR/>1. ANTIPSYCHOTIC AGENTS<BR/>2. antipsychotic$<BR/>3. neuroleptic$<BR/>4. (amisulpride or chlormethiazole or (chlorpromazine next hydrochloride) or chlorprothixene or clozapine or dixyrazine or (flupenthixol next decanoate) or (fluphenazine next decanoate) or haloperidol or levomepromazine or loxapine or (melperone next hydrochloride) or methotrimeprazine or olanzapine or perphenazine or pimozide or (prothipendyl next hydrochloride) or (quetiapine next fumarate) or risperidone or sulpiride or thioridazine or (tiapride next hydrochloride) or (trifluoperazine next hydrochloride) or ziprasidone or zotepine or zuclopenthixol)<BR/>5. OR/1-4<BR/>6. PAIN (Explode term)<BR/>7. VASCULAR HEADACHES (Explode term)<BR/>8. PAIN MEASUREMENT<BR/>9. neuralgi$<BR/>10 pain$<BR/>11. migrain$<BR/>12. OR/6-11<BR/>13. 5 AND12<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-09-04 14:25:44 +0100" MODIFIED_BY="Stefan Seidel" NO="3">
<TITLE MODIFIED="2013-09-04 11:36:44 +0100" MODIFIED_BY="Stefan Seidel">Updated searches January 2013</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-04 14:25:44 +0100" MODIFIED_BY="Stefan Seidel">
<P>
<B>MEDLINE (OVID) Oct 2011 to 11/01/13</B>
</P>
<P>1 Antipsychotic Agents/ (38296)</P>
<P>2 (antipsychotic* or neuroleptic*).tw. (36477)</P>
<P>3 (neurolept* or antipsychotic* or Amisulpride* or Chormethiazole* or Clomethiazole* or Distraneurin* or Chlorpromazin* or Aminazine* or Chlorazine* or Chlordelazine* or Contomin* or Fenactil* or Largactil* or Propaphenin* or Thorazine* or "Flupenthixol decanoate* or Emergil*" or Fluanxol* or Flupentixol* or alphaFlupenthixol* or cisFlupenthixol* or Fluphenazin* or "Fluphenazine decanoate*" or Flufenazin* or "Fluphenazine Hydrochloride*" or Lyogen* or Prolixin* or Haloperidol* or Haldol* or Levomepromazin* or Levomeprazin* or Levopromazine* or Tisercin* or Tizercine* or Tizertsin* or Methotrimeprazine* or Loxapine* or Loxapinsuccinate* or Oxilapine* or Cloxazepine* or "Loxapine Monohydrochloride*" or "Loxipine Maleate*" or "Loxipine Succinate*" or Loxitane* or Asendin* or Desmethylloxapine* or Amoxapine* or Olanzapine* or Perphenazine* or Chlorpiprazine* or Perfenazine* or Trilafonor* or Pimozide* or Prothipendyl* or Quetiapine* or Fumarate* or Risperidone* or Risperidal* or Sulpiride* or Dogmatil* or Eglonyl* or Sulperide* or Thioridazine* or Meleril* or Mellaril* or Melleril* or Melleryl* or Sonapax* or "Thioridazine Hydrochloride*" or Tiaprid* or Tiapridal* or "Trifluoperazine Hydrochloride*" or Trifluoroperazine* or Triftazin* or Stelazine* or "Trifluperazine*or Tripfluoperazine Hydrochloride*or Cisordinol*" or "Zuclopenthixol*or Clopenthixol*,or Clozapine*or Melperone hydrochloride*or Ziprasidone*or Zotemine*").mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (99220)</P>
<P>4 Pimozide/ (1648)</P>
<P>5 Perphenazine/ (1405)</P>
<P>6 exp Loxapine/ (547)</P>
<P>7 Methotrimeprazine/ (670)</P>
<P>8 Haloperidol/ (14331)</P>
<P>9 Fluphenazine/ (2275)</P>
<P>10 Flupenthixol/ (809)</P>
<P>11 Chlorpromazine/ (15304)</P>
<P>12 Chlormethiazole/ (751)</P>
<P>13 Clopenthixol/ (360)</P>
<P>14 Trifluoperazine/ (3342)</P>
<P>15 Tiapride Hydrochloride/ (0)</P>
<P>16 Thioridazine/ (2154)</P>
<P>17 Sulpiride/ (3544)</P>
<P>18 Risperidone/ (4655)</P>
<P>19 Fumarates/ (3100)</P>
<P>20 or/1-19 (102158)</P>
<P>21 exp Pain/ (282471)</P>
<P>22 pain*.tw. (378943)</P>
<P>23 or/21-22 (504903)</P>
<P>24 20 and 23 (1768)</P>
<P>25 randomized controlled trial.pt. (336937)</P>
<P>26 controlled clinical trial.pt. (84917)</P>
<P>27 randomized.ab. (240687)</P>
<P>28 placebo.ab. (134089)</P>
<P>29 drug therapy.fs. (1568585)</P>
<P>30 randomly.ab. (172962)</P>
<P>31 trial.ab. (247676)</P>
<P>32 groups.ab. (1131458)</P>
<P>33 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 (2921812)</P>
<P>34 exp animals/ not humans.sh. (3747051)</P>
<P>35 33 not 34 (2482012)</P>
<P>36 24 and 35 (1002)</P>
<P>37 (201110* or 201111* or 201112* or 2012*).ed. (946315)</P>
<P>38 36 and 37 (51)</P>
<P>
<B>CENTRAL (The Cochrane Library) Issue 12 of 12 (2012)</B>
</P>
<P>#1 MeSH descriptor: [Antipsychotic Agents] this term only</P>
<P>#2 (antipsychotic* or neuroleptic*)</P>
<P>#3 (neurolept* or antipsychotic* or Amisulpride* or Chormethiazole* or Clomethiazole* or Distraneurin* or Chlorpromazin* or Aminazine* or Chlorazine* or Chlordelazine* or Contomin* or Fenactil* or Largactil* or Propaphenin* or Thorazine* or Flupenthixol decanoate* or Emergil* or Fluanxol* or Flupentixol* or alphaFlupenthixol* or cisFlupenthixol* or Fluphenazin* or Fluphenazine decanoate* or Flufenazin* or Fluphenazine Hydrochloride* or Lyogen* or Prolixin* or Haloperidol* or Haldol* or Levomepromazin* or Levomeprazin* or Levopromazine* or Tisercin* or Tizercine* or Tizertsin* or Methotrimeprazine* or Loxapine* or Loxapinsuccinate* or Oxilapine* or Cloxazepine* or Loxapine Monohydrochloride* or Loxipine Maleate* or Loxipine Succinate* or Loxitane* or Asendin* or Desmethylloxapine* or Amoxapine* or Olanzapine* or Perphenazine* or Chlorpiprazine* or Perfenazine* or Trilafonor* or Pimozide* or Prothipendyl* or Quetiapine* or Fumarate* or Risperidone* or Risperidal* or Sulpiride* or Dogmatil* or Eglonyl* or Sulperide* or Thioridazine* or Meleril* or Mellaril* or Melleril* or Melleryl* or Sonapax* or Thioridazine Hydrochloride* or Tiaprid* or Tiapridal* or Trifluoperazine Hydrochloride* or Trifluoroperazine* or Triftazin* or Stelazine* or "Trifluperazine*or Tripfluoperazine Hydrochloride* or Cisordinol*" or Zuclopenthixol* or Clopenthixol* or Clozapine*or Melperone hydrochloride* or Ziprasidone* or Zotemine*)</P>
<P>#4 MeSH descriptor: [Pimozide] this term only</P>
<P>#5 MeSH descriptor: [Perphenazine] this term only</P>
<P>#6 MeSH descriptor: [Loxapine] explode all trees</P>
<P>#7 MeSH descriptor: [Methotrimeprazine] this term only</P>
<P>#8 MeSH descriptor: [Haloperidol] this term only</P>
<P>#9 MeSH descriptor: [Fluphenazine] this term only</P>
<P>#10 MeSH descriptor: [Flupenthixol] this term only</P>
<P>#11 MeSH descriptor: [Chlorpromazine] this term only</P>
<P>#12 MeSH descriptor: [Chlormethiazole] this term only</P>
<P>#13 MeSH descriptor: [Clopenthixol] this term only</P>
<P>#14 MeSH descriptor: [Trifluoperazine] this term only</P>
<P>#15 MeSH descriptor: [Thioridazine] this term only</P>
<P>#16 MeSH descriptor: [Sulpiride] this term only</P>
<P>#17 MeSH descriptor: [Risperidone] this term only</P>
<P>#18 MeSH descriptor: [Fumarates] this term only</P>
<P>#19 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18</P>
<P>#20 MeSH descriptor: [Pain] explode all trees</P>
<P>#21 pain*</P>
<P>#22 #20 or #21</P>
<P>#23 #19 and #22 from 2011 to 2013</P>
<P>
<B>EMBASE (OVID) Oct 2011 to 2013 week 03</B>
</P>
<P>1 Antipsychotic Agents/ (58700)</P>
<P>2 (antipsychotic* or neuroleptic*).tw. (55785)</P>
<P>3 (neurolept* or antipsychotic* or Amisulpride* or Chormethiazole* or Clomethiazole* or Distraneurin* or Chlorpromazin* or Aminazine* or Chlorazine* or Chlordelazine* or Contomin* or Fenactil* or Largactil* or Propaphenin* or Thorazine* or "Flupenthixol decanoate* or Emergil*" or Fluanxol* or Flupentixol* or alphaFlupenthixol* or cisFlupenthixol* or Fluphenazin* or "Fluphenazine decanoate*" or Flufenazin* or "Fluphenazine Hydrochloride*" or Lyogen* or Prolixin* or Haloperidol* or Haldol* or Levomepromazin* or Levomeprazin* or Levopromazine* or Tisercin* or Tizercine* or Tizertsin* or Methotrimeprazine* or Loxapine* or Loxapinsuccinate* or Oxilapine* or Cloxazepine* or "Loxapine Monohydrochloride*" or "Loxipine Maleate*" or "Loxipine Succinate*" or Loxitane* or Asendin* or Desmethylloxapine* or Amoxapine* or Olanzapine* or Perphenazine* or Chlorpiprazine* or Perfenazine* or Trilafonor* or Pimozide* or Prothipendyl* or Quetiapine* or Fumarate* or Risperidone* or Risperidal* or Sulpiride* or Dogmatil* or Eglonyl* or Sulperide* or Thioridazine* or Meleril* or Mellaril* or Melleril* or Melleryl* or Sonapax* or "Thioridazine Hydrochloride*" or Tiaprid* or Tiapridal* or "Trifluoperazine Hydrochloride*" or Trifluoroperazine* or Triftazin* or Stelazine* or "Trifluperazine*or Tripfluoperazine Hydrochloride*or Cisordinol*" or "Zuclopenthixol*or Clopenthixol*,or Clozapine*or Melperone hydrochloride*or Ziprasidone*or Zotemine*").mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (194441)</P>
<P>4 Pimozide/ (7142)</P>
<P>5 Perphenazine/ (6563)</P>
<P>6 exp Loxapine/ (1943)</P>
<P>7 Methotrimeprazine/ (4973)</P>
<P>8 Haloperidol/ (49400)</P>
<P>9 Fluphenazine/ (8860)</P>
<P>10 Flupenthixol/ (4196)</P>
<P>11 Chlorpromazine/ (42097)</P>
<P>12 Chlormethiazole/ (2771)</P>
<P>13 Clopenthixol/ (767)</P>
<P>14 Trifluoperazine/ (9676)</P>
<P>15 Tiapride Hydrochloride/ (1713)</P>
<P>16 Thioridazine/ (11514)</P>
<P>17 Sulpiride/ (10861)</P>
<P>18 Risperidone/ (24372)</P>
<P>19 Fumarates/ (1849)</P>
<P>20 or/1-19 (199428)</P>
<P>21 exp Pain/ (727482)</P>
<P>22 pain*.tw. (554811)</P>
<P>23 or/21-22 (949124)</P>
<P>24 20 and 23 (13310)</P>
<P>25 random$.tw. (790580)</P>
<P>26 factorial$.tw. (20622)</P>
<P>27 crossover$.tw. (46266)</P>
<P>28 cross over$.tw. (21047)</P>
<P>29 cross-over$.tw. (21047)</P>
<P>30 placebo$.tw. (189432)</P>
<P>31 (doubl$ adj blind$).tw. (140094)</P>
<P>32 (singl$ adj blind$).tw. (13242)</P>
<P>33 assign$.tw. (219299)</P>
<P>34 allocat$.tw. (74370)</P>
<P>35 volunteer$.tw. (169764)</P>
<P>36 Crossover Procedure/ (36012)</P>
<P>37 double-blind procedure.tw. (224)</P>
<P>38 Randomized Controlled Trial/ (338179)</P>
<P>39 Single Blind Procedure/ (16894)</P>
<P>40 or/25-39 (1296258)</P>
<P>41 (animal/ or nonhuman/) not human/ (4558955)</P>
<P>42 40 not 41 (1142927)</P>
<P>43 24 and 42 (2327)</P>
<P>44 (201110* or 201111* or 201112* or 2012* or 2013*).dd. (1627558)</P>
<P>45 43 and 44 (276)</P>
<P>
<B>PsycINFO (OVID) 2011 to Jan week 3 2013</B>
</P>
<P>1 Neuroleptic Drugs/ (13626)</P>
<P>2 (antipsychotic* or neuroleptic*).tw. (24917)</P>
<P>3 (neurolept* or antipsychotic* or Amisulpride* or Chormethiazole* or Clomethiazole* or Distraneurin* or Chlorpromazin* or Aminazine* or Chlorazine* or Chlordelazine* or Contomin* or Fenactil* or Largactil* or Propaphenin* or Thorazine* or "Flupenthixol decanoate* or Emergil*" or Fluanxol* or Flupentixol* or alphaFlupenthixol* or cisFlupenthixol* or Fluphenazin* or "Fluphenazine decanoate*" or Flufenazin* or "Fluphenazine Hydrochloride*" or Lyogen* or Prolixin* or Haloperidol* or Haldol* or Levomepromazin* or Levomeprazin* or Levopromazine* or Tisercin* or Tizercine* or Tizertsin* or Methotrimeprazine* or Loxapine* or Loxapinsuccinate* or Oxilapine* or Cloxazepine* or "Loxapine Monohydrochloride*" or "Loxipine Maleate*" or "Loxipine Succinate*" or Loxitane* or Asendin* or Desmethylloxapine* or Amoxapine* or Olanzapine* or Perphenazine* or Chlorpiprazine* or Perfenazine* or Trilafonor* or Pimozide* or Prothipendyl* or Quetiapine* or Fumarate* or Risperidone* or Risperidal* or Sulpiride* or Dogmatil* or Eglonyl* or Sulperide* or Thioridazine* or Meleril* or Mellaril* or Melleril* or Melleryl* or Sonapax* or "Thioridazine Hydrochloride*" or Tiaprid* or Tiapridal* or "Trifluoperazine Hydrochloride*" or Trifluoroperazine* or Triftazin* or Stelazine* or "Trifluperazine*or Tripfluoperazine Hydrochloride*or Cisordinol*" or "Zuclopenthixol*or Clopenthixol*,or Clozapine*or Melperone hydrochloride*or Ziprasidone*or Zotemine*").mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests &amp; measures] (32805)</P>
<P>4 Pimozide/ (196)</P>
<P>5 Perphenazine/ (103)</P>
<P>6 exp Loxapine/ (45)</P>
<P>7 Haloperidol/ (3295)</P>
<P>8 Fluphenazine/ (257)</P>
<P>9 Chlorpromazine/ (363)</P>
<P>10 Trifluoperazine/ (44)</P>
<P>11 Thioridazine/ (145)</P>
<P>12 Sulpiride/ (370)</P>
<P>13 Risperidone/ (2980)</P>
<P>14 exp Pain/ (33805)</P>
<P>15 pain*.tw. (60478)</P>
<P>16 or/14-15 (67780)</P>
<P>17 or/1-13 (32819)</P>
<P>18 16 and 17 (485)</P>
<P>19 clinical trials/ (6454)</P>
<P>20 (randomis* or randomiz*).tw. (39468)</P>
<P>21 (random$ adj3 (allocat$ or assign$)).tw. (22565)</P>
<P>22 ((clinic$ or control$) adj trial$).tw. (33593)</P>
<P>23 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw. (15295)</P>
<P>24 (crossover$ or "cross over$").tw. (5462)</P>
<P>25 random sampling/ (445)</P>
<P>26 Experiment Controls/ (435)</P>
<P>27 Placebo/ (2888)</P>
<P>28 placebo$.tw. (23824)</P>
<P>29 exp program evaluation/ (12478)</P>
<P>30 treatment effectiveness evaluation/ (11837)</P>
<P>31 ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw. (45024)</P>
<P>32 or/19-31 (141635)</P>
<P>33 18 and 32 (82)</P>
<P>34 limit 33 to yr="2011 -Current" (17)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>